SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

--------------------

FORM 10-K

ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF
THE SECURITIES EXCHANGE ACT OF 1934

For The Year Ended December 31, 1997 Commission File No. 0-26816

--------------------------

IDX Systems Corporation
(Exact Name of Registrant as Specified in its Charter)

-------------------

Vermont 03-0222230
(State or Other Jurisdiction of (I.R.S. Employer
Incorporation or Organization Identification No.)

1400 Shelburne Road, P.O. Box 1070, South Burlington, Vermont 05403
(Address of Principal Executive Offices) (Zip Code)

-------------------

Registrant's telephone number, including area code: (802) 862-1022

Securities registered pursuant to Section 12(b) of the Act: NONE

Securities registered pursuant to Section 12(g) of the Act:

Title of each class
Common Stock, $.01 par value

-------------------

Indicate by check mark whether the registrant (1) has filed all reports
required to be filed by Section 13 or 15(d) of the Securities Exchange Act of
1934 during the preceding 12 months (or for such shorter period that the
registrant was required to file such reports), and (2) has been subject to such
filing requirements for the past 90 days.

Yes X No
--- ---

Indicate by check mark if disclosure of delinquent filers pursuant to Item
405 of Regulation S-K is not contained herein, and will not be contained, to the
best of registrant's knowledge, in definitive proxy or information statements
incorporated by reference in Part III of this Form 10-K or any amendment to the
Form 10-K.

The aggregate market value of voting Common Stock held by nonaffiliates of
the registrant was $541,864,449 based on the last reported sale price of the
Common Stock on the Nasdaq consolidated transaction reporting system on March
16, 1998.

Number of shares outstanding of the registrant's class of Common Stock as
of March 16, 1998: 26,263,353.

Documents incorporated by reference: Proxy Statement for the 1998 Annual
Meeting of Stockholders--Part II and Part III

PART I

Item 1. Business

IDX SYSTEMS CORPORATION

Business

Overview

IDX is a leading provider of healthcare information solutions in the United
States. IDX offers healthcare information solutions that include software,
hardware, and related services required by physician groups, management services
organizations (MSOs), health plans, hospitals and integrated delivery networks
(IDNs). IDX solutions enable healthcare organizations to redesign patient care
and other workflow processes in order to improve efficiency and quality.

On July 10, 1997, IDX successfully completed the acquisition of PHAMIS, Inc
(PHAMIS), a Seattle-based provider of patient-centered acute care clinical
information systems, including the LastWord(R) system. The Company acquired
PHAMIS by means of a merger (the "Merger") of a subsidiary of the Company with
and into PHAMIS, with PHAMIS remaining as the surviving corporation and becoming
a wholly owned subsidiary of the Company following the Merger. The Merger was
accounted for as a pooling of interests in the quarter ended September 30, 1997.
In September 1997, PHAMIS was merged with and into the Company. The LastWord
system provides the depth of functionality required to manage the complex accute
care setting, with special emphasis on the clinical process. The merger enhances
the Company's competitive status by positioning the Company to deliver a
complete information solution to healthcare delivery systems. The solution is
packaged as the IDXtendR(TM) @ the Site Series, where the Site corresponds to
settings across the care continuum: IDXtendR(TM) @ the Group practice,
IDXtendR(TM) @ the MSO, IDXtendR(TM) @ the Health Plan, IDXtendR(TM) @ the
Hospital, and IDXtendR(TM) @ IDN. The IDXtendR product line, which employs
relational, scaleable, client/server architecture, combines the strengths of the
IDX and LastWord applications to provide both ambulatory and hospital
capabilities.

As of February 28, 1998 IDX's systems were used by, or were under contract
to be used by, more than 96,500 physicians and were installed at over 1,550
client sites, including approximately 230 large physician group practices, those
generally with more than 75 physicians, more than 550 physician practices which
have 75 or fewer physicians, over 260 hospitals and a growing number of IDNs.

IDX was incorporated in Vermont on June 2, 1969. IDX's executive offices
are located at 1400 Shelburne Road, South Burlington, Vermont 05403 and its
telephone number is (802) 862-1022.

Industry Background

Healthcare costs in the United States have risen dramatically over the past
two decades relative to the overall rate of inflation. Broad pressures to reduce
costs without sacrificing the quality of care have caused significant changes in
the healthcare industry. While reimbursement for healthcare has historically
been based on a fee-for-service model of payment, managed care organizations and
other payers are increasingly utilizing alternative reimbursement models,
including fixed fee and capitation, that shift the financial risk of delivering
healthcare from payers to both physicians and institutional providers. Pressures
to control costs have also contributed to the movement of care from more
expensive inpatient settings, such as hospitals, to ambulatory settings. Today,
ambulatory care providers, particularly physician groups, deliver the majority
of healthcare services, bear an increasing share of the financial risk, and
control a substantial portion of total healthcare resources.

In order to compete in the changing healthcare environment, individual
physicians, physician groups and other ambulatory care providers are
increasingly joining and affiliating with other physicians, managed care
organizations, hospitals and other enterprises to form larger healthcare
organizations known as IDNs. These organizations are designed to manage the
continuum of healthcare services for population groups across both inpatient and
ambulatory settings, while achieving improved quality and reduced costs for
patients and members. In the emerging managed care environment, IDNs are
increasingly entering into contracts that often define the terms under which
care is administered and may fix the amount of payment for each covered life.
One of the key

challenges facing IDNs and the market today is improving the quality of care
while reducing the associated cost. To do this, IDNs must organize their
businesses to efficiently manage patient care and other workflow processes that
may extend across multiple care locations and business entities. Many health
care organizations are working to control and influence the complete treatment
during an episode (or entire lifetime) of care. The resulting risk-sharing
arrangements associated with managed care are causing providers--physicians,
group practices, clinics, and hospitals--to focus on the critical role that
physicians play in determining the cost and quality of care.

To compete under the constraints of managed care, while maintaining the
quality of care, healthcare organizations have placed increasing demands on
their information systems. Initially, these organizations required financially
oriented systems which focused on reducing costs by automating certain financial
and administrative functions. As it became necessary to manage patient flow
processes and not just individual tasks, the need arose to exchange information
stored in disparate systems through computer-to-computer interfaces. However,
due to the limitations of such interfaces and the complexities of these larger
organizations, IDNs and physician groups began to require fully-integrated
systems that seamlessly integrate their enterprise. Such information systems
must enable the implementation of enterprise-wide patient flow processes that
create a longitudinal record of administrative, financial and clinical
information from multiple entities, while focusing on the physician as the
primary care giver. In addition, large healthcare organizations increasingly
require information systems that can deliver high-performance computing in
environments with thousands of concurrent computer users.

To function as fully integrated delivery systems, IDNs need integrated
clinical, financial, and administrative information systems. These systems
support the organization's efforts to streamline patient flow, reduce costs and
improve the quality of care. At the same time, information systems must provide
the ability to access and analyze the information each organization needs to
make the complex business and care decisions IDNs face today.

The healthcare information systems market is highly fragmented, with over
1,300 vendors. It is estimated that the market, worth an estimated $11.6 billion
in 1996, could grow to as much as $18.0 billion by the year 2000. Healthcare
organizations are transitioning to new platforms and newer technologies in a
migration over time toward the implementation of enterprise-wide, patient-
centered computing systems leading to the computerized medical record. These
organizations cannot afford significant downtime or re-education, or the risk of
choosing a system which has not proven its ability to handle high-volume
transaction processing with continuous dependability. IDX believes that
successful vendors in this market will have a large existing client base and
offer the high quality, fully integrated products and value-added services
needed to expand and support clients throughout this evolution process.

Strategy

IDX seeks to maximize value for its clients by delivering information
systems that are designed to improve the quality and reduce the cost of
healthcare delivery. The IDX strategy is to build on its success as a leading
ambulatory systems vendor and to build on the strength of the LastWord acute
care clinical system to provide complete information systems solutions for IDNs
and other healthcare organizations. The IDX solution anticipates evolutionary
change in IDNs and provides the connectivity and information sharing functions
that support evolutionary change. IDX systems also allow physician groups to
share data with an IDN while at the same time maintaining an appropriate level
of autonomy. This approach recognizes the real operational needs of hospitals,
MSOs, group practices, and health plans while simultaneously achieving the
critical physician link to the network.

The combined strengths of the IDX and LastWord systems position IDX to
provide depth of product function across administrative, financial, clinical,
and analytical applications. The IDX strategy--which includes automating patient
care and other workflow processes, web-access to patient data, and enterprise
clinicals--provides benefits to IDNs looking to attract and maintain strong
physician relationships. The Company's understanding of the significant role of
the physician and the evolutionary nature of the IDN is the cornerstone of the
IDX strategy.

Key elements of IDX's strategy are to:

Increase Penetration of IDNs through Large Physician Group and
Hospital Customer Relationships. IDX believes that its existing client base,
including approximately 230 large group practices comprised of over 79,000
physicians and over 260 hospitals, as of February 28, 1998, will play a
significant role in the formation and management of IDNs. As a result of the
Company's relationships with these clients and the depth and breadth of the
functions and service offerings available, IDX anticipates that significant
opportunities will exist to sell its products and services to IDNs and their
affiliated organizations.

Capitalize on Growth of Group Practice Market. The number of
physicians practicing medicine in a group setting has increased significantly in
recent years. IDX believes the number and size of such groups will continue to
grow as economic pressures drive physicians to affiliate with or form new,
larger group practices. IDX believes its position as a leading provider of
integrated information solutions to physician groups, particularly those with 75
or more physicians, and its proven ability to meet their needs will allow IDX to
capitalize on the continued growth of the group practice market.

Cross-Sell Products and Services into Existing Client Base. IDX
believes significant opportunities exist to cross-sell current products and
professional services as well as products under development to its existing
client base at February 28, 1998, consisting of over 775 physician practices
with 89,500 physicians and over 260 hospitals. IDX is marketing its LastWord
system to IDNs associated with its ambulatory customers, and is marketing the
IDX ambulatory solution to physician groups associated with the LastWord
customer base. In addition to selling products that enhance currently installed
ambulatory applications, IDX actively markets applications that complement
currently installed IDX systems. Among those applications are the IDXtendRTM
Clinical Management System--an ambulatory computerized patient record;
Analyzer--an OLAP (online analytical processing) decision support tool;
Electronic Data Interchange--for interactive eligibility and credit card
processing; IDXrad--radiology information system; Enterprise Patient Management
System--an enterprise master patient index system; and OutReach(TM)--a web-based
companion application to IDX systems.

Sell Solutions to Solve Customers' Business Needs. IDX believes it can
be successful by combining its products and services to provide a complete
solution to the information systems challenges of healthcare organizations.
Solutions are configured as the IDXtendR @ the Site SeriesTM , which is
comprised of IDXtendR @ the Group Practice (Series 2000); IDXtendR @ the MSO
(Series 3000); IDXtendR @ the Health Plan (Series 4000); IDXtendR @ the Hospital
(Series 5000); and IDXtendR @ the IDN (Series 6000). The @ the Site Series
includes core applications, optional applications, and complementary products
and services.

Expand Professional and Technical Service Offerings. IDX seeks to
leverage its healthcare information systems expertise providing professional and
technical services such as information systems planning, contract programming,
and project management to assist healthcare organizations. A specialized
consulting organization within IDX, The Huntington Group, provides information
technology solutions to healthcare organizations, including process redesign,
organizational change management, outsourcing, and systems integration services
to IDX customers. IDX has alliances with US Servis, Inc. for business office
outsourcing, and Daou Systems, Inc. for network design and implementation. IDX
markets professional and technical services primarily to organizations that
currently use IDX's information systems products.

Migrate Clients to Proven Technologies. To reduce risks of changing
technologies and ensure that IDX customers have tools needed to operate in
complex clinical and business office settings, IDX strives to utilize technology
for performance by applying the new technologies as they prove themselves able
to perform well in large-scale, transaction-driven environments. The technology
for performance philosopy seeks to protect customer investments in current
systems with a technology framework designed to allow them to expand and take
advantage of new features and new technologies as they become available. The IDX
technical strategy is based on thin client architecture as the basis for World
Wide Web access to applications to allow more convenient desktop device
independence and reduce costs of training and equipment. To support standardized
reporting and analysis, IDX strives to utilize SQL databases running under
Microsoft Windows NT, and to support more natural product

integration. IDX also strives to develop component-based software oriented
around business objects which contain logic of healthcare business processes.

Establish Partnerships to Supplement IDX Offerings. IDX seeks to
enhance its product offerings through strategic alliances with vendors
developing complementary products. The complementary products and services
currently offered include integrated credit card transaction processing,
point-of-service access to eligibility, referral, and enrollment data,
integrated patient communication systems, and billing office outsourcing. In
addition to increasing the range of products and services available to IDX
customers, these alliances provide recurring revenue opportunities for IDX.

IDX Products

Products

IDX's software product solutions enable healthcare organizations to
redesign patient care and other work flow processes by providing computer-based
tools to capture, access and manage information within healthcare organizations
and throughout IDNs. In January 1997, IDX introduced the IDXtendR(TM) product
line. IDXtendR is packaged as the "IDXtendR @ the Site Series" consisting of
nine configurations of IDX products packaged to meet the specific process
requirements of healthcare organizations, including group practices, MSOs,
health plans, hospitals, and IDNs. IDXtendR provides relational reporting and
analysis capabilities as well as OutReach for web-browser access to patient data
residing in an IDX database. Below is a description of IDX's products as of
February 28, 1998.

Key healthcare processes automated by the IDXtendR product line include:

- - patient information access applications focusing on scheduling and patient
registration processes

- - financial management applications for billing and health plan management

- - clinical information applications, including the LastWord(R) lifetime
computerized patient record system, the Clinical Management System (CMS) for
ambulatory clinical information, and IDXrad for radiology information and image
management

- - enterprise connectivity applications such as Enterprise-wide Scheduling,
Enterprise Patient Management, OutReach, and EDI for connecting hospitals and
other provider sites throughout the delivery network

- - decision support applications such as Analyzer, Management Reporter, and
Enterprise Perspective, providing comprehensive relational reporting tools to
support effective decision-making across the care continuum

Key functional areas within the applications of the IDXtendR @ the Site Series
include:

Patient Information Access
Scheduling:

- schedules patients, providers, and resources in small, mid-size, and
large physician group settings

- manages schedules and coordinates appointments in the acute care
environment and is integrated with orders for procedure scheduling

Registration:

- stores patient demographics and insurance information

- creates a single master database of patient information across
multiple care settings

- includes patient registration, charge entry, fee schedule, patient
list, user registration, security and text messaging functions.

Visit Management:

- admission and discharge capabilities for outpatient centers, physician
practices, and clinics

- admission, discharge, and transfer capabilities for hospital inpatients
and outpatients

- reports information related to patient registration, visit, bed
management, and insurance management

- tracks every patient interaction to build the complete electronic
medical record

Charting

- provides abstracting and encoding using ICD-9, CPT-4 and DRG codes.

- streamlines chart completion activities for medical records personnel

- streamlines all activities related to tracking physical medical records
throughout a multi-site organization

- automates activities related to releasing patient record information to
external requesters including tracking, billing and collection.

Financial and Managed Care
Billing and Accounts Receivable:

- integrates billing and receivables management with comprehensive
analysis and reporting for large group practices and MSOs

- manages patient billing, collection and insurance management from
initial registration through resolution of payment

- streamlines hospital patient accounting activities and expedites
reimbursement

Managed Care Application

maintains member registration, demographic, and financial data and
automatically applies benefits as defined in the member's plan

- provides a comprehensive referrals system with authorization tracking,
concurrent review, pre-certification, length of stay assignment, and
provider selection

- provides case identification, care plan tracking, cost simulation, form
letters, and linking of service records

- adjudicates and processes claims and statistical encounters

- provides billing for employer groups and self-pay members and manages
receivables

- provides flexible risk management (fund accounting), tracking, and
reporting

- provides issue tracking, responsibility assignment, workflow management
with automatic ticklers, and letter production

Transaction Editing System (TES):

- captures, evaluates, and facilitates editing of charge and claim data

- allows transactions to be edited for completeness and re-tested before
they are entered into BAR and MCA applications

Contract Reference:

- manages capitated contracts across the enterprise

Clinical Information
Clinical Tools

- manages the care process by providing a patient record, access to a
structured medical knowledge database that supports protocols, and
outcomes management

- complete set of tools to aid clinician productivity and streamline
workflow, including problem list, prescription pad, chart summary view,
provider in-box and alerts, health maintenance alerts, patient list
management, panel query and rounds report.

- provides clinical results in easy to read flowsheet format.

- provides automated support for nursing activities such as assessments,
charting, and patient classification.

Orders and Results Reporting

- provides complete order management capabilities for inpatient and
ambulatory settings.

- provides complete results reporting for lab, ancillary, radiology,
medications, and diagnosis results.

Pharmacy

- comprehensive inpatient pharmacy department support

- comprehensive outpatient pharmacy department support

Emergency Department

- provides patient flow management and tracking support for the emergency
department that is fully integrated with the inpatient system, making
all care activities performed in the ED available as part of the
patient's long-term record.

Enterprise and Departmental Radiology

- automates a radiology department's clinical, demographic,
administrative, billing, scheduling, and film information

- provides multiple-site, access to patient data, exam information,
results, and corresponding digital images, thereby reducing instances
of film loss and delays in reporting to physicians

- makes images and diagnostic reports available throughout the enterprise
via imaging solutions including a modality manager (in development --
investigational device)

- provides bi-directional link between IDXrad and diagnostic imaging
equipment, allowing transfer of information between the modality and
IDXrad (in development -- investigational device)

Enterprise Connectivity
Enterprise Patient Management System (EPMS):

- a master person index used to track patient and member registration
information and visit histories across multiple locations in a delivery
network

Enterprise Wide Scheduling (EWS):

- provides enterprise-wide patient, provider, and resource scheduling

OutReach:

- provides web browser access to patient information residing in IDXtendR
Electronic Data Interchange (EDI):

- automates the computer-to-computer exchange of data such as claims
submittals and remittances, health plan eligibility information, and
integrated credit card processing

Decision Support
Analyzer:

- provides relational reporting and analysis of IDXtendR data using
Microsoft SQL Server and on-line analytical processing (OLAP) for
multi-dimensional analysis in a graphical user environment

Enterprise View:

- provides a data repository for enterprise-wide information analysis
using a relational database

Business Partner Solutions
Envoy:

- provides point-of-service access to claims and receipts, interactive
eligibility, enrollment, and referral services.

- eliminates formatting challenges typically associated with electronic
data interchange (EDI)

HDX:

- provides seamless access to eligibility information at the point of
service

- integrated with EDI to enable requesting, receiving, and updating
eligibility information

Imperial Technology Solutions:

- provides credit card transaction processing services from the IDX
desktop integrated with EDI for automatic approval and payment posting
into the patient's account

Picis:

- PICIS Chart+ - critical care system used with the LastWord system

Point-of-Care Systems (POC):

- POC Pegasus(TM) - home care system used with the LastWord system

SmartTalk:

- provides an integrated patient communication solution based on
Interactive Voice Response (IVR) technology

- utilizes a sophisticated voice messaging engine to provide personalized
appointment reminders and confirmation, schedule change notification,
wellness and recall message delivery, around the clock test result
delivery, and patient surveys

- integrated with the Patient Scheduling (SCHED) application

Services

IDX maintains a client services organization to install, support and
provide professional, technical and other services to its client base. IDX
possesses the healthcare information systems expertise desired by the growing
number of larger and more sophisticated healthcare enterprises as they
reengineer healthcare delivery processes and

implement information systems to support these processes. The services
organization is experienced at installing and supporting systems in very large
organizations with thousands of computer users across multiple departments.

Installation Services. IDX's installation representatives work with clients
to tailor and optimize IDX products to meet specific business needs. Services
include project management, train-the-trainer programs, best practices
comparison to other IDX clients and systems conversion and implementation
assistance.

Maintenance Services. IDX provides ongoing software support to all of its
large clients and substantially all of its other clients under contracts that
are typically for a term of one year. These contracts generally are renewable
automatically unless terminated at the option of either the client or IDX.
Software maintenance services consist of providing the client with certain new
software releases and general support, including error corrections and telephone
consultation. For all products, maintenance services are available either on a
24-hour-a-day basis or during normal business hours.

Professional and Technical Services. IDX offers professional and technical
services to assist clients in building an information infrastructure to operate
in a complex and changing healthcare environment. The work performed by IDX
includes information systems planning, process redesign, project management,
contract programming, network design, education and training. These value-added
services, combined with IDX's systems expertise, enable IDX to support its
clients' efforts to develop consistent enterprise-wide systems and processes.
Through these services, IDX believes it strengthens its relationship with
clients, builds a knowledge base of best practices in the use of IDX's systems
and gains information regarding future client needs. IDX has expanded the
services provided by this group with the formation of The Huntington Group, a
professional services organization devoted to providing information technology
solutions to those organizations that use IDX's information systems products.

The following sets forth a description of the key functional areas within the
IDX consulting organization:

IDX Professional Services

The Huntington Group

- process redesign, organizational change management, outsourcing, and
systems integration

Technical Consulting Services

- performance and investment analysis and hardware upgrades, network
review, systems operational analysis, and various utilities and tools
including - IDX Address Corrector, IDXfax, and IDX Open Access

Application Consulting Services

- project management, upgrades, temporary services, and operational
analysis

Network Consulting Services

- network analysis, design, and implementation, temporary networking
services, client server design and installation, and support services

Radiology Consulting Services

- system analysis and process redesign for radiology groups

Technical Platforms and Hardware

IDX designs its software to operate on a variety of technical platforms,
including computer equipment from Digital Equipment Corporation ("DEC"), Tandem
Computer, a Compaq Company, Hewlett Packard Company ("HP") and International
Business Machines Corporation ("IBM"). The LastWord system operates on Tandem's
NonStop computing platform, which is designed to support high-volume, mission-
critical applications and can be expanded without adversely affecting system
responsiveness or interrupting existing online users. The Tandem server supports
large-scale, high-performance SQL database access and is designed for inter-
operability with other computing systems.

The IDX technology strategy is based on a technology for performance
philosophy employing advanced technology and connectivity solutions to solve
business problems. The fundamental components of our technical strategy include:

- - Web-based, thin client architecture as the basis for access, enabling
greater convenience for users, allowing desktop device independence and reducing
costs for training and equipment

- - SQL databases running under Microsoft Windows NT, supporting a
standardized approach to reporting and analysis

- - Component-based software written as Business Objects (as defined below),
resulting in more naturally integrated products because of the unique way in
which Business Objects can represent real world concepts.

Component-based software written as Business Objects is a software design
methodology that uses concepts and actions by describing their attributes in a
programming language. Once a concept or action has been described, that
description and its accompanying software code can be reused broadly as the
building blocks for different applications. This software design approach leads
to faster development processes and allows IDX to "plug" components together in
tailored configurations providing greater congruence with client needs and
expectations.

The architecture of IDX products is expected to enable clients to
incrementally migrate from one technology to another. With a focus on reliable,
scaleable hardware and software solutions, all IDX applications will migrate to
platform independence, beginning with a migration to SQL and Windows NT. IDX
believes that its approach to technology, particularly the emphasis on web-
based, thin client architecture, will provide IDX customers with flexibility and
utility, while reducing costs and deployment risks.

As a service to its clients, IDX sells third-party computers, terminals,
printers, storage devices and other peripheral devices. IDX also provides
value-added services to configure client systems. Hardware is purchased from
DEC, IBM, Tandem, and HP under renewable one-year reseller agreements. IDX does
not maintain an inventory of hardware, but relies on suppliers' inventories to
meet client delivery requirements. IDX believes that its relationships with
vendors are good.

Sales and Marketing

IDX sells its products exclusively through its direct sales force. The
majority of IDX's sales calls are in response to requests for proposals. IDX
generates these requests and other sales primarily through referrals from
clients and consultants. IDX also seeks to enhance market recognition through
participation in industry seminars and trade shows, direct mail campaigns,
telemarketing and advertisements in trade journals.

IDX's direct sales force is organized into two divisions: Enterprise
Systems ("ES"), which sells the ambulatory, inpatient and IDN products and the
Radiology and Imaging Solutions Division ("RISD"), which sells IDXrad, IDXview
and EMIMS. ES products typically have a three to 18 month sales cycle for new
client sales. RISD products typically have six to 18 month sales cycles for new
client sales.

No single client accounted for more than 5% of IDX's annual revenues in
fiscal 1995, 1996, or 1997.

At December 31, 1997, the Company had total backlog of $203.1 million,
including $101.5 million attributable to systems sales and $101.7 million
attributable to services. Systems sales backlog consists of fees due under
signed contracts which have not yet been recognized as revenues. Service backlog
represents contracted software maintenance services, installation fees, and
remote computing services fees for a period of 12 months. At December 31, 1996,
the Company had total backlog of $212.8 million including $135.0 million
attributable to systems sales and $77.8 million attributable to services for
multiple years of services. Service backlog represents contracted software
maintenance services, installation fees, and remote computing services fees for
a period of 12 months or greater at December 31, 1996. Of the total 1997 backlog
of $203.1 million, the Company expects that $22.5 million will not be fulfilled
in the current fiscal year.

Product Development

To ensure that its products continue to meet the evolving needs of the
healthcare industry, IDX allocates a significant portion of annual revenues to
research and development. IDX's research and development expenses for the fiscal
years 1995, 1996 and 1997 were $23.4 million, $29.8 million, and $36.3 million
respectively.

IDX's product development activities include enhancement of existing
products and the development of new products, as well as the implementation of
new technologies. IDX is devoting significant resources to integrating the
LastWord and IDX products, developing a relational practice management solution,
and expanding its web-based architecture. IDX is also currently migrating its
products to client/server platforms with graphical user interfaces and

relational databases. IDX's development process is focused on building
components for its integrated product rather than on stand-alone products. These
components can be integrated and configured to address specific client needs.
IDX utilizes client focus groups, user groups and industry experts, including
physicians, nurses, healthcare administrators and consultants, for advice in
developing and enhancing its products.

Competition

The market for healthcare information systems is highly competitive. IDX
believes that the principal competitive factors in this market are the ability
to effectively market, install, support and integrate systems, the resources to
support ongoing research and development, financial stability and price. IDX
believes it competes favorably with respect to these factors. Competitors vary
in size, and in the scope and breadth of the products and services offered. IDX
experiences competition from companies with strengths in various segments of the
healthcare information systems market, such as physician group practice systems,
hospital information systems, clinical information systems, ancillary
departmental systems and systems integration. In addition, other entities not
currently offering products and services similar to those offered by IDX,
including claims processing organizations, hospitals, third-party
administrators, insurers, healthcare organizations and others, may enter certain
markets in which IDX competes.

While IDX believes no vendor dominates the market for healthcare
information systems, certain of IDX's competitors have greater financial,
development, technical, marketing and sales resources than IDX and have a
greater penetration into segments of the market in which IDX competes. In
addition, as the markets for IDX's products and services develop, additional
competitors may enter those markets and competition may intensify.

Proprietary Rights and Licenses

IDX depends upon a combination of trade secret, copyright and trademark
laws, license agreements, nondisclosure and other contractual provisions and
technical measures to protect its proprietary rights in its products. IDX
distributes its products under software license agreements which grant clients a
nonexclusive, nontransferable license to use IDX's products and contain terms
and conditions prohibiting the unauthorized reproduction or transfer of IDX's
products. In addition, IDX attempts to protect its trade secrets and other
proprietary information through agreements with employees and consultants. All
current employees of IDX have signed a nondisclosure agreement, and all current
employees involved in product development have signed an assignment of
inventions agreement. There can be no assurance that the legal protections
afforded to IDX or the precautions taken by IDX will be adequate to prevent
misappropriation of IDX's technology. In addition, these protections do not
prevent independent third-party development of functionally equivalent or
superior technologies, products or services. Any infringement or
misappropriation of IDX's proprietary software would disadvantage IDX in its
efforts to retain and attract new clients in a highly competitive market and
could cause IDX to lose revenues or incur substantial litigation expense. IDX
believes that, due to the rapid pace of innovation within the software industry,
factors such as the technological and creative skills of its personnel and
ongoing reliable product maintenance and support are more important in
establishing and maintaining a leadership position within the industry than are
the various legal protections afforded to its technology.

Although IDX believes that its products, trademarks and other proprietary
rights do not infringe upon the proprietary rights of third parties, there can
be no assurance that third parties will not assert infringement claims against
IDX in the future and that such claims will not have a material adverse effect
on IDX's results of operations, financial condition or business.

Government Regulation

demonstrate safety or effectiveness, or substantial equivalence. If the FDA
requires such data, IDX would be required to obtain approval of an
investigational device exemption before undertaking clinical trials. Clinical
trials can take extended periods of time to complete and there can be no
assurance that the FDA will approve or clear a device after the completion of
such trials. In addition, such software products would be subject to the FDC
Act's general controls, including those relating to good manufacturing practices
and adverse experience reporting. Although it is not possible to anticipate the
final form of the FDA's policy with regard to computer software, IDX expects
that, whether or not the draft is finalized or changed, the FDA is likely to
become increasingly active in regulating computer software that is intended for
use in healthcare settings. The FDA can impose extensive requirements governing
pre- and post-market conditions such as device investigation, approval, labeling
and manufacturing. In addition, the FDA can impose extensive requirements
governing development controls and quality assurance processes. There can be no
assurance that actions taken by the FDA to regulate computer software products
will not have a material adverse effect on IDX's results of operations,
financial condition or business.

Employees

At December 31, 1997, IDX employed 1,833 full-time employees. As of
December 31, 1997, IDX's sales force was comprised of 194 employees responsible
for the entire sales process. As of December 31, 1997, IDX's client services
group consisted of 1,092 employees and IDX had 365 employees engaged primarily
in program development, new technology adaption and quality assurance. No
employees are covered by any collective bargaining agreements.
IDX believes that its employee relations are good.

Item 2. Properties

The Company's principal corporate offices are located at 1400 Shelburne
Road, South Burlington, Vermont 05403. The Company maintains sales, research and
support facilities in South Burlington, Vermont, Boston, Massachusetts, and
Seattle, Washington. The Company maintains regional sales and support offices in
the greater metropolitan areas of Arlington, Virginia, Chicago, Illinois,
Dallas, Texas, San Francisco, California and Atlanta, Georgia. The Company
leases all of its facilities which, in the aggregate, constitute approximately
511,500 rentable square feet of office space, under leases expiring between
February 28, 1999 and April 12, 2014. The Company believes that its facilities
are adequate for its current needs and that suitable additional space will be
available as required.

Item 3. Legal Proceedings

None.

Item 4. Submission of Matters to a Vote of Security Holders

No matters were submitted to a vote of security holders of the Company,
through solicitation of proxies or otherwise, during the last quarter of the
year ended December 31, 1997.

EXECUTIVE OFFICERS OF THE REGISTRANT

The following sets forth: (i) the name and age of each present executive
officer of the Company, (ii) the position(s) currently held by each named
person, and (iii) the principal occupations held by each person named for at
least the past five years.

Executive Officer Age Position
- --------------------------------- --- ---------------------------------------------------------

Richard E. Tarrant............... 55 President, Chief Executive Officer, and Director

Henry M. Tufo, M.D. ............. 57 Executive Vice President, Chief Operating Officer, and Director

Robert W. Baker, Jr., Esq. ...... 49 Vice President, General Counsel, and Secretary

Jeffrey M. Blanchard............. 41 Vice President, Client Services

James H. Crook, Jr. ............. 41 Vice President

Robert F. Galin.................. 53 Vice President, Sales

John A. Kane..................... 45 Vice President, Finance and Administration, Chief Financial
Officer, and Treasurer

Pamela J. Pure................... 37 Vice President, Marketing

Jeffrey V. Sutherland, Ph.D. .... 56 Senior Vice President, Engineering and Product Development

Mr. Tarrant co-founded the Company in 1969 and has served as the President
and Chief Executive Officer of the Company and as a Director since that time.
Mr. Tarrant served as a member of the Board of Trustees for the University
Health Center (Vermont), an academic medical center, from July 1988 to December
1994 and as Chairman of the University Health Center (Vermont) from 1992 to
1994.

Dr. Tufo has been Executive Vice President of the Company since September
1995. Dr. Tufo has served as a Director of the Company since November 1995. Dr.
Tufo has served as Chief Operating Officer of the Company since September 1996.
Dr. Tufo served as Vice President and Chief Medical Officer of the Company from
August 1995 to September 1995. Dr. Tufo served as a consultant to the Company
from February 1995 to August 1995. Dr. Tufo was the President and Chief
Executive Officer of University Health Center (Vermont) from July 1989 to
December 1994. Dr. Tufo is Professor of Medicine at the University of Vermont
College of Medicine.

Mr. Baker, who joined the Company in July 1989, has served as Vice
President of the Company since April 1996. Mr. Baker has served as General
Counsel and Secretary of the Company since July 1989.

Mr. Blanchard, who joined the Company in August 1987, has served as Vice
President, Client Services of the Company since March 1995. Prior to that time,
Mr. Blanchard served the Company in various capacities, including most recently
as Director, Customer Support from November 1992 to March 1995.

Mr. Crook, who joined the Company in April 1981, has served as Vice
President of the Company since June 1984. He served as a Director of the Company
from July 1984 to June 1995.

Mr. Galin has served as Vice President, Sales since August 1992. He served
as Director of Sales from April 1982 to August 1992.

Mr. Kane has served as the Vice President, Finance and Administration,
Chief Financial Officer and Treasurer of the Company since joining the Company
in October 1984. Mr. Kane is a C.P.A.

Ms. Pure has served as Vice President, Marketing since November 1995. Ms.
Pure served as Director of Best Practices from March 1995 to November 1995.
Prior to joining the Company, Ms. Pure was employed by Shared Medical Systems
Corporation, a medical software company, from May 1983 until March 1995, most
recently as Manager of Product Marketing and Communications.

Dr. Sutherland has served as Senior Vice President, Engineering and
Product Development since joining the Company in September 1996. Prior to
joining the Company, he was Vice President, Engineering of Individual Inc., an
Internet content provider company, from May to September 1996; Vice President,
Object Technology of Vmark Software, a software development tools company, from
June 1995 to May 1996; Vice President, Object Technology for Easel Corporation,
a software development tools company, from July 1993 to June 1995; and President
and founder of Object Databases (now known as Matisse Software) from October
1989 to June 1993.

Each officer serves at the discretion of the Company's Board of Directors.
There are no family relationship among the named officers.

The portion of the response to this item relating to arrangements and
understandings pursuant to which named executive officers were or are to be
elected as officers of the Company is contained in the Company's Proxy Statement
for the 1998 Annual Meeting of Stockholders to be held on May 18, 1998 (the
"1998 Proxy Statement") under the caption "Employment Agreements" and is
incorporated herein by reference.

PART II

Item 5. Market for Registrant's Common Equity and Related Stockholder Matters

(a) Market Price of and Dividends on Common Stock and Related Matters. The
Common Stock of IDX Systems Corporation is traded on the Nasdaq Market under the
symbol "IDXC." The following table sets forth for the periods indicated the high
and low sales prices per share of the Common Stock as reported by the Nasdaq
National Market.

Quarter/Year High Low
----------------------------------------------------- ------- -------
1996

First Quarter 1996................................... $ 36.625 $ 27.25
(January 1, 1996 through March 31, 1996)

Second Quarter 1996.................................. $ 44.25 $ 28.25
(April 1, 1996 through June 30, 1996)

Third Quarter 1996................................... $ 40.50 $ 24.75
(July 1, 1996 through September 30, 1996)

Fourth Quarter 1996.................................. $ 35.75 $ 22.50
(October 1, 1996 through December 31, 1996)

1997
First Quarter 1997................................... $ 36.50 $ 26.875
(January 1, 1997 through March 31, 1997)

Second Quarter 1997.................................. $ 37.50 $ 23.0
(April 1, 1997 through June 30, 1997)

Third Quarter 1997................................... $ 40.00 $ 31.5
(July 1, 1997 through September 30, 1997)

Fourth Quarter 1997.................................. $ 38.00 $ 28.375
(October 1, 1997 through December 31, 1997)

On March 16, 1998, the Company had approximately 188 stockholders of
record. (This number does not include stockholders for whom shares are held in a
"nominee" or "street" name.) On March 16, 1998, the closing price of the
Company's Common Stock on the Nasdaq National Market was $43.50.

The Company anticipates that all future earnings will be retained for
development of its business and will not be distributed to stockholders as
dividends. Restrictions or limitations on the payment of dividends may be
imposed in the future under the terms of credit agreements or under other
contractual provisions. In the absence of such restrictions or limitations, the
payment of any dividends will be at the discretion of the Company's Board of
Directors.

(b) Recent Sales of Unregistered Securities. On June 18, 1997, the Company
issued 300 shares of Common Stock to each of the three outside directors of the
Company in consideration of one year's past service as a director of the
Company. The shares of Common Stock issued in these transactions were offered
and sold in reliance upon the exemption from registration under Section 4(2) of
the Securities Act of 1933, as amended (the "Securities Act"), relating to sales
by an issuer not involving any public offering. All such securities are deemed
restricted securities for purposes of the Securities Act. There were no
underwriters involved in such transactions.

(c) Use of Proceeds. The Company is furnishing the following information
with respect to the use of proceeds from its initial public offering of Common
Stock, $.01 per share, which closed on November 22, 1995.

(1) The effective date of the Registration Statement on Form S-1
for the offering was November 16, 1995 and the commission
file number of the Registration Statement is 33-97104.
(2) The offering commenced on November 16, 1995.
(3) Not applicable.
(4) (i) The offering terminated on November 18, 1995 after all
the shares were sold.
(ii) The managing underwriters for the offering were BT
Alex. Brown and Volpe, Welty & Company.
(iii) The Company registered shares of the Company's Common
Stock, $.01 par value per share, in the offering.
(iv) Of the 4,634,500 shares of Common Stock registered in
the offering, 4,604,500 shares were registered for the
account of the Company, and 30,000 shares were
registered for the account of a selling stockholder.
All such shares registered for the account of the
Company and for the account of the selling stockholder
were sold in the offering on November 22, 1995. The
aggregate offering prices of the shares registered and
sold for the accounts of the Company and selling
stockholder were $82,881,000 and $540,000,
respectively.
(v) From November 16, 1995 to December 31, 1997, the actual
expenses incurred in connection with the offering,
including underwriting discounts, commissions and other
expenses, were (i) $39,926 paid to directors,
officers, general partners of the Company and their
associates, persons owning 10% or more of the equity
securities of the Company and affiliates of the Company
and (ii) $6,677,244 paid to others.
(vi) The net offering proceeds to the Company after expenses
were approximately $76,163,830.
(vii) From November 16, 1995 to December 31, 1997,
$36,657,330 of the offering proceeds were actually
distributed to stockholders of the Company. This amount
represented the Company's previously undistributed
earnings as an S Corporation from July 1987 through
October 1995 (the "S Corporation Distribution"). The S
Corporation Distribution was paid in November 1995 and
December 1995. $36,630,206 of the S Corporation
Distribution was paid to directors, officers, general
partners of the Company and their associates, persons
owning 10% or more of the equity securities of the
Company and affiliates of the Company and $27,124 of
the S Corporation Distribution was paid to other
stockholders of the Company. From November 16, 1995 to
December 31, 1997, $39,506,500, the balance of the
offering proceeds were used for general corporate
purposes, including working capital purposes, the
payment of current expenses and the acquisition of
businesses. As of December 31, 1997, the offering
proceeds had been fully applied by the Company.
(viii) Not applicable.

Item 6. Selected Financial Data

Financial Highlights

Summary of Consolidated Financial Data

Year Ended December 31,
------------------------------------------------------
1993 1994 1995 1996 1997
------------------------------------------------------
(in thousands, except per share data)

Statements of Income Data:
Revenues.............................................. $ 117,710 $ 143,807 $ 175,285 $ 206,879 $ 251,417
Operating Income...................................... 4,745 9,348 19,038 22,626 10,614
Net Income............................................ 4,379 7,229 20,673 16,660 7,962
Net Income Per Share.................................. $ 0.64 $ 0.30
Pro Forma Net Income.................................. 4,854 13,915
Pro Forma Net Income Per Share........................ $ 0.24 $ 0.63

Balance Sheet Data:
Cash and Investments.................................. $ 24,712 $ 30,786 $ 104,154 $ 113,392 $ 115,887
Working Capital....................................... 30,924 33,662 110,966 131,900 140,906
Total Assets.......................................... 81,052 96,013 169,517 202,322 237,318
Long-term Debt, less current portion.................. 8,502 7,070 3,059 2,651 2,508
Total Stockholders' Equity............................ $ 50,923 $ 60,899 $ 130,512 $ 158,550 $ 176,604

The consolidated financial data set forth above has been restated to include
the results of operations and accounts of PHAMIS for all periods prior to its
acquisition by IDX on July 10, 1997. The acquisition, as more fully described in
Note 2 to the Consolidated Financial Statements, has been accounted for as a
pooling of interests.

Per share amounts represent diluted net income per share. The 1994 and 1995
pro forma net income per share and the 1996 net income per share amounts have
been restated to comply with Statement of Financial Accounting Standards No.
128, Earnings per Share, as more full described in Note 1 to the Consolidated
Financial Statements.

Item 7. Management's Discussion and Analysis of Financial Condition and
Results of Operations

General

The acquisition of PHAMIS was completed on July 10, 1997, and has been
accounted for as a pooling of interests. Therefore, the results of operations
for all periods discussed below have been restated to include the financial
results of PHAMIS. See Note 2 of Notes to Consolidated Financial Statements.

Revenues of $251.4 million in 1997 grew 21.5% over 1996 revenues of $206.9
million. Systems sales grew 21.7% in 1997, and maintenance and service fees
grew 21.3%.

Operating income declined from $22.6 million in 1996 to $10.6 million in
1997, a decrease of $12.0 million or 53.1%. Excluding expenses related to the
write-off of acquired research and development and merger and related costs,
operating income grew from $22.9 million in 1996 to $32.9 million in 1997, an
increase of $10.0 million or 43.7%. Net income declined from $16.7 million in
1996 to $8.0 million in 1997, a decrease of $8.7 million or 52.1%. Excluding the
write-off of acquired research and development, and merger and related costs,
net income grew from $16.7 million in 1996 to $23.1 million in 1997, an increase
of $6.4 million or 38.3%.

This Management's Discussion and Analysis of Financial Condition and
Results of Operations includes a number of forward-looking statements which
reflect the Company's current views with respect to future events and financial
performance. These forward-looking statements are subject to certain risks and
uncertainties, including those discussed below, that could cause actual results
to differ materially from historical results or those anticipated. The Company
has identified by italics, or all capital letters, various sentences within this
Annual Report which contain such forward-looking statements. In addition, words
such as "believes," "may," "plans," "anticipates," "expects," "intends," and
similar expressions are intended to identify forward-looking statements, but are
not

the exclusive means of identifying such statements. In addition, the
disclosures on page 19 under the caption "Factors Affecting Future Results,"
which are not italicized or capitalized for improved readability, consist
principally of a discussion of risks which may affect future results and, are
thus, in their entirety forward-looking in nature. Readers are urged to
carefully review and consider the various disclosures made by the Company in
this report and in the Company's other reports filed with the Securities and
Exchange Commission that attempt to advise interested parties of the risks and
factors that may affect the Company's business.

Year Ended December 31, 1997 and 1996

Revenues. The Company's total revenues increased to $251.4 million in 1997
from $206.9 million in 1996, an increase of $44.5 million or 21.5%. Revenues
from systems sales increased to $134.5 million in 1997 (53.5% of total revenues)
from $110.5 million (53.4% of total revenues) in 1996, an increase of $24.0
million or 21.7%. The increase was primarily due to an increase in installations
of certain of the Company's IDXtend and LastWord systems. Revenues from
maintenance and service fees increased to $116.9 million in 1997 (46.5% of total
revenues) from $96.4 million (46.6% of total revenues) in 1996, an increase of
$20.5 million or 21.3%. Approximately $11.1 million of the increase was due to
additional maintenance revenue resulting from the continued growth in the
Company's installed client base. Professional and technical services revenues
increased to $20.4 million in 1997 (8.1% of total revenues) from $12.6 million
in 1996 (6.1% of total revenues), an increase of $7.8 million as a result of the
Company's increased marketing efforts in that area.

Cost of Sales. The cost of sales and services increased to $130.4 million
in 1997 from $108.3 million in 1996, an increase of $22.1 million or 20.4%. The
gross profit margin on systems sales and services increased to 48.1% in 1997
from 47.7% in 1996. The increase in gross profit was due primarily to the
increase of additional license revenues in the installations of certain of the
Company's products from its IDXtend and LastWord systems.

Selling, General and Administrative Expenses. Selling, general and
administrative expenses increased to $51.7 million in 1997 from $45.9 million in
1996, an increase of $5.8 million or 12.6%. As a percentage of total revenues,
selling, general and administrative expenses decreased to 20.6% in 1997 from
22.2% in 1996. The additional expenses incurred in 1997 were primarily due to an
increase in the Company's sales and marketing staff.

Research and Development. Research and development expenses increased to
$36.3 million in 1997 from $29.8 million in 1996, an increase of $6.5 million or
21.8%. The increase was due to the hiring of additional staff to support the
development of additional products for the Company. As a percentage of total
revenues, research and development expenses remained constant at 14.4% in 1997
and 1996. As described in Note 1 to the consolidated financial statements,
software development costs incurred subsequent to the establishment of
technological feasibility until general release of the related products are
capitalized. Prior to the merger technological feasibility was determined
differently by IDX and PHAMIS. Subsequent to the merger the Company's
determination of technological feasibility for all product development is based
on the completion of a working model which has been approved for beta site
testing. Historically costs incurred during beta site testing have not been
material. Although the Company presently expects costs to complete beta site
testing in the future to be insignificant, as the Company develops products to
operate using other technologies as well as more comprehensive clinical systems,
the time and effort required to complete beta site testing may be significantly
more extensive. Consequently, capitalized software development costs may become
material in future reporting periods.

Merger and Related Costs. During the third quarter of 1997, the Company
recorded charges of $20.0 million related to the merger with PHAMIS. The charges
were comprised of transaction costs of $5.1 million, write-offs and adjustments
of $7.4 million of long-lived assets, principally capitalized software
development costs and equipment, attributable to the elimination of overlapping
products and operations, employee termination and related costs of $2.7 million,
and other merger related costs of $4.8 million, principally related to
integration costs incurred during the year and the termination of leases and
other contractual obligations. At December 31, 1997, accounts payable and
accrued expenses include accrued costs of $3.1 million related to the
termination of employees, leases and other contractual obligations,
substantially all of which will be paid within one year. The write-off of long-
lived assets is not expected to materially affect amortization or depreciation
of future reporting periods. In addition, the provision for termination of
employees, leases and other contractual obligations is not expected to
materially affect selling, general or administrative expenses or cash flows of
future periods. Management does not expect to incur significant charges related
to the merger in future reporting periods.

Write-off of Acquired In-Process Research and Development. On February 26,
1997, the Company recorded charges of $2.3 million related to the acquisition of
certain data model technology from Medaphis Healthcare Information Technology
Company for cash of $2.5 million. The acquisition was accounted for under the
purchase method. The charges were expensed as in-process research and
development in connection with the Company's development of a healthcare data
model.

Year Ended December 31, 1996 and 1995.

Revenues. The Company's total revenues increased to $206.9 million in 1996
from $175.3 million in 1995, an increase of $31.6 million or 18.0%. Revenues
from systems sales increased to $110.5 million in 1996 (53.4% of total revenues)
from $94.2 million (53.7% of total revenues) in 1995, an increase of $16.3
million or 17.3%. The increase was primarily due to an increase in installations
of the Company's IDXtendR @ the Group Practice product, (formerly known as the
IDXtend Ambulatory Suite). Revenues from maintenance and service fees increased
to $96.4 million) in 1996 (46.6% of total revenues) from $81.1 million (46.3% of
total revenues) in 1995, an increase of $15.3 million or 18.8%. Approximately
$9.6 million of the increase was due to additional maintenance revenue resulting
from the continued growth in the Company's installed client base. Professional
and technical services revenues increased approximately $4.2 million in 1996
over 1995 as a result of the Company's increased marketing efforts in that area.

Cost of Sales. The cost of sales and services increased to $108.3 million
in 1996 from $96.8 million in 1995, an increase of $11.5 million or 11.9%. The
gross profit margin on systems sales and services increased to 47.7% in 1996
from 44.8% in 1995. The increase in gross profit was due primarily to the
increase in the installations of the Company's IDXtendR @ the Group Practice
product, (formerly known as the IDXtend Ambulatory Suite).

Selling, General and Administrative Expenses. Selling, general and
administrative expenses increased to $45.9 million in 1996 from $36.1 million in
1995, an increase of $9.8 million or 27.1%. As a percentage of total revenues,
selling, general and administrative expenses increased to 22.2% in 1996 from
20.6% in 1995. This percentage increase was largely attributable to costs
incurred by PHAMIS in 1996 related to entry into the international market,
corporate headquarters' relocation and a business acquisition. Additional
expenses incurred in 1996 in addition to the PHAMIS related costs were primarily
due to the increase in the Company's sales and marketing staff over the same
period in 1995.

Research and Development. Research and development expenses increased to
$29.8 million in 1996 from $23.4 million in 1995, an increase of $6.4 million or
27.4%. The increase was due to the hiring of additional staff to support the
development of additional products for the Company. As a percentage of total
revenues, research and development expenses increased to 14.4% in 1996 from
13.4% in 1995.

Liquidity and Capital Resources

Since its inception in 1969, the Company has funded its operations, working
capital needs and capital expenditures primarily from operations, except for
real estate owned by certain partnerships and trusts financed through industrial
development bonds. The proceeds from its initial public offering were (i)
distributed to stockholders of the Company in connection with the Company's
prior status as an S corporation under the Internal Revenue Code of 1986, as
amended, and (ii) used for general corporate purposes, including working capital
purposes, payment of current expenses and strategic transactions, including
acquisitions of businesses, products and technologies.

Cash flows from operations are principally comprised of net income and
depreciation and are primarily affected by the net effect of the change in
accounts receivable, accounts payable and accrued expenses. Due to the nature of
the Company's business, accounts receivable, deferred revenue and accounts
payable fluctuate considerably due to, among other things, the length of the
sales cycle and installation efforts which are dependent upon the size of the
transaction, the changing business plans of the customer, the effectiveness of
customers' management and general economic conditions. In general accounts
receivable from customers have been collected consistently within 95 days.

Cash flows related to investing activities have principally been related to
the purchase of computer and office equipment, leasehold improvements, and the
purchase and sale of investment grade marketable securities. THE COMPANY
EXPECTS THESE ACTIVITIES TO CONTINUE. INVESTING ACTIVITIES MAY ALSO INCLUDE
PURCHASES OF INTERESTS IN AND ACQUISITIONS OF COMPLEMENTARY PRODUCTS,
TECHNOLOGIES AND BUSINESSES. There can be no assurance that the Company will be
able to successfully complete any such purchases or acquisitions in the future.

Cash, cash equivalents and marketable securities at December 31, 1997 were
$115.9 million, an increase of $2.5 million from December 31, 1996. The majority
of the increase was due to the cash provided by operating activities and
proceeds related to the exercise of stock options. The Company has a revolving
line of credit with a bank allowing the Company to borrow up to $5.0 million
bearing interest at the prime rate. There were no borrowings as of December 31,
1997 or 1996.

THE COMPANY EXPECTS THAT ITS REQUIREMENTS FOR OFFICE FACILITIES AND OTHER
OFFICE EQUIPMENT WILL GROW AS STAFFING REQUIREMENTS DICTATE. The Company's
operating lease commitments consist primarily of office leasing for the
Company's operating facilities. THE COMPANY PLANS TO CONTINUE INCREASING THE
NUMBER OF ITS PROFESSIONAL STAFF DURING 1998 TO MEET ANTICIPATED SALES VOLUME
AND TO SUPPORT RESEARCH AND DEVELOPMENT EFFORTS. tO THE EXTENT NECESSARY TO
SUPPORT INCREASES IN STAFFING, THE COMPANY INTENDS TO OBTAIN ADDITIONAL OFFICE
SPACE.

THE COMPANY BELIEVES THAT CURRENT OPERATING FUNDS WILL BE SUFFICIENT TO
FINANCE ITS OPERATING REQUIREMENTS AT LEAST THROUGH DECEMBER 1998. To date,
inflation has not had a material impact on the Company's revenues or income.

Income Taxes

From July 12, 1987 to November 1, 1995, the Company was treated for federal
and certain state income tax purposes as an S Corporation under the Internal
Revenue Code of 1986, as amended (the "Code"). As a result, the Company's
stockholders, rather than the Company, were required to pay federal and certain
state income taxes based upon the Company's earnings whether or not the earnings
were distributed to such stockholders. On November 1, 1995, the Company
terminated its S Corporation status and, accordingly, has become subject to
federal and state income taxes.

For purposes of financial statement presentations, the Company's financial
statements reflect comparative pro forma financial information for 1995 as if
the Company had been fully taxed. The provision for income taxes for the year
ended December 31, 1997 was provided for at the taxable income rate of
approximately 50%, which is higher than the historical rate of 40%. This higher
rate is due to a portion of the charges incurred in the merger with PHAMIS,
principally transaction costs, which are non-deductible for income tax purposes.
FOR 1998, THE COMPANY ANTICIPATES AN EFFECTIVE TAX RATE OF APPROXIMATELY 40% OF
PRE-TAX INCOME.

New Accounting Standards

In October, 1997, the American Institute of Certified Public Accountants
issued Statement of Position ("SOP") 97-2, Software Revenue Recognition,
revising certain aspects of SOP 91-1. The SOP is effective for transactions
occurring in years beginning after December 15, 1997. THE COMPANY DOES NOT
EXPECT THE sop WILL MATERIALLY AFFECT ITS REVENUE RECOGNITION POLICIES WITH
RESPECT TO SOFTWARE LICENSE FEES WHICH ARE BASED UPON VENDOR-SPECIFIC OBJECTIVE
INFORMATION AND RELATE PRINCIPALLY TO ITS PROPRIETARY SYSTEMS SOFTWARE WHICH
GENERALLY REQUIRES NO SIGNIFICANT PRODUCTION, MODIFICATION OR CUSTOMIZATION.
LICENSE REVENUE, ACCORDINGLY, IS DEFERRED AND RECOGNIZED AS CUSTOMER PAYMENTS
BECOME DUE BASED UPON SPECIFIED MILESTONES AND DUE DATES INCLUDING DELIVERY,
INSTALLATION AND FINAL SYSTEMS ACCEPTANCE.

In 1998, the Company will be required to adopt Statements of Financial
Accounting Standards (SFAs) No. 130 and No. 131, "Reporting Comprehensive
Income" and "Disclosures About Segments of an Enterprise and Related
Information." THE COMPANY BELIEVES THE ADOPTION OF THESE NEW ACCOUNTING
STANDARDS WILL NOT HAVE A MATERIAL IMPACT ON THE COMPANY'S FINANCIAL STATEMENTS.

In 1997, the Financial Accounting Standards Board issued SFAS No. 128,
Earnings per Share. SFAS No. 128 replaced the calculation of primary and fully
diluted earnings per share with basic and diluted earnings per share. Unlike
primary earnings per share, basic earnings per share excludes any dilutive
effects of options, warrants and convertible securities. Diluted earnings per
share is similar to the previously reported fully diluted earnings per share.

Backlog

At December 31, 1997, the Company had total backlog of $203.1 million,
including $101.5 million attributable to systems sales and $101.7 million
attributable to services. Systems sales backlog consists of fees due under
signed contracts which have not yet been recognized as revenues. Service backlog
represents contracted software maintenance services, installation fees, and
remote computing services fees for a period of 12 months. At December 31, 1996,
the Company had total backlog of $212.8 million including $135.0 million
attributable to systems sales and $77.8 million attributable to services for
multiple years of services. Service backlog represents contracted software
maintenance services, installation fees, and remote computing services fees for
a period of 12 months or greater at December 31, 1996. OF THE TOTAL 1997 BACKLOG
OF $203.1 MILLION, THE COMPANY EXPECTS THAT $22.5 MILLION WILL NOT BE FULFILLED
IN THE CURRENT FISCAL YEAR.

Year 2000

THE COMPANY HAS ASSESSED ITS INTERNAL USE SYSTEMS AND ITS CURRENTLY
SUPPORTED PRODUCTS FOR POSSIBLE PROBLEMS IN PROCESSING, REPORTING, DISPLAYING
AND OTHERWISE HANDLING DATE DATA CONTAINING THE YEAR 2000 AND BEYOND. tHE
cOMPANY BELIEVES IT HAS FORMULATED AND IS IN THE PROCESS OF IMPLEMENTING OR HAS
COMPLETED ALL PLANS TO MAKE YEAR 2000 READY ALL OF ITS CRITICAL INTERNAL USE
SYSTEMS AND ALL OF ITS CURRENTLY SUPPORTED PRODUCTS.

AT DECEMBER 31, 1997, ALL OF THE CORE DATA BASES AND DATA PROCESSING
FUNCTIONS OF THE COMPANY'S SIGNIFICANT PRODUCTS WERE YEAR 2000 READY. THE
COMPANY EXPECTS THAT ELEMENTS OF THE COMPANY'S PRODUCTS OTHER THAN CORE
DATABASES AND DATA PROCESSING FUNCTIONS, SUCH AS CERTAIN SCREENS AND REPORTS,
WILL BE YEAR 2000 READY IN 1998. THE COMPANY HAS EXPENSED AMOUNTS INCURRED AS OF
DECEMBER 31, 1997 TO MAKE SUCH PRODUCTS YEAR 2000 READY, AND SUCH AMOUNTS HAVE
NOT BEEN MATERIAL. THE ADDITIONAL COSTS TO MAKE ALL SUCH REMAINING SYSTEMS YEAR
2000 READY BY THE END OF 1998 WILL BE EXPENSED AS INCURRED, ARE EXPECTED TO BE
INCURRED IN 1998 AND ARE NOT EXPECTED TO BE MATERIAL.

THE COMPANY UNDER ITS MAINTENANCE AGREEMENTS EXPECTS TO COMMENCE
DELIVERY TO ITS INSTALLED CUSTOMERS OF YEAR 2000 READY VERSIONS OF ALL OF ITS
SIGNIFICANT PRODUCTS IN 1998 AND TO COMPLETE MOST INSTALLATIONS OF SUCH VERSIONS
BY MID 1999. THE COSTS TO INSTALL YEAR 2000 READY VERSIONS OF THE COMPANY'S
PRODUCTS AT CUSTOMER SITES, AS WELL AS THE ABILITY OF THE COMPANY TO ASSIST
CUSTOMERS IN THE INSTALLATION OF YEAR 2000 READY VERSIONS OF ITS PRODUCTS, WILL
DEPEND IN PART ON THE READINESS, ABILITY AND COOPERATION OF CUSTOMERS TO INSTALL
SUCH VERSIONS.

ANY OF THE cOMPANY'S INTERNAL USE SYSTEMS AND ANY OF THE PRODUCTS
SUPPLIED BY THE COMPANY TO ITS CUSTOMERS COULD FAIL TO ADEQUATELY OR PROPERLY
PROCESS, DISPLAY, REPORT, OR OTHERWISE HANDLE DATE DATA CONTAINING THE YEAR 2000
AND BEYOND. ANY FAILURE OF A CUSTOMER TO BE READY OR ABLE TO TIMELY INSTALL yEAR
2000 READY VERSIONS OF THE COMPANY'S PRODUCTS COULD CAUSE SIGNIFICANT
OPERATIONAL PROBLEMS FOR THE CUSTOMER. FURTHER, A FAILURE OF THE COMPANY TO
TIMELY MAKE AVAILABLE YEAR 2000 READY VERSIONS OF ITS PRODUCTS, OR A FAILURE OF
THE COMPANY TO TIMELY PROVIDE ADEQUATE RESOURCES TO ASSIST ITS CUSTOMERS IN
INSTALLING YEAR 2000 READY VERSIONS OF ITS PRODUCTS, COULD RESULT IN CLAIMS BY
CUSTOMERS, WHICH MAY HAVE A MATERIAL ADVERSE EFFECT ON THE BUSINESS, OPERATIONS,
AND FUTURE FINANCIAL RESULTS OF THE COMPANY.

Factors Affecting Future Results

The Company's revenues and operating results can vary significantly
from quarter to quarter as a result of a number of factors, including the volume
and timing of systems sales and installations, and length of sales cycles and
installation efforts. The timing of revenues from systems sales is difficult to
forecast because the Company's sales cycle can vary depending upon factors such
as the size of the transaction, the changing business plans of the customer, the
effectiveness of customer's management, and general economic conditions. In
addition, because revenue is recognized at various points during the
installation process, the timing of revenue recognition varies considerably
based on a number of factors, including availability of personnel, availability
of the customer's resources and complexity of the needs of the customer's
organization. The Company's initial contact with a potential customer depends in
significant part on the customer's decision to replace, expand, or substantially
modify its existing information systems, or modify or add business processes or
lines of business. How and when to implement, replace, expand or substantially
modify an information system or modify or add business processes or lines of
business, are major decisions for healthcare organizations. Accordingly, the
sales cycle for the Company's systems is typically three to eighteen months or
more from contract execution to completion of installation. During the sales
cycle and the installation cycle, the Company expends substantial time, effort
and funds preparing contract proposals, negotiating the contract and
implementing the system. Because a significant percentage of the Company's
expenses are relatively fixed, a variation in the timing of systems sales and
installation can cause significant variations in operating results from quarter
to quarter. The Company's future operating results may fluctuate as a result of
these and other factors, such as customer purchasing patterns, and the timing of
new product and service introductions and product upgrade releases. The Company
believes that quarterly results of operations will continue to be subject to
significant fluctuations and that its results of operations for any particular
quarter or fiscal year may not be indicative of results of operations for future
periods. There can be no assurance that future period to period fluctuations
will continue and will not have a material adverse effect on the Company's
results of operations, financial condition or business.

The Company intends to continue to grow in part through acquisitions of
complementary products, technologies and businesses or alliances with
complementary businesses. The Company's ability to expand successfully through
acquisitions or alliances depends on many factors, including the successful
identification and acquisition of products, technologies or businesses and
management's ability to effectively integrate and operate the acquired or
aligned products, technologies or businesses. There is significant competition
for acquisition and alliance opportunities in the healthcare information systems
industry, which may intensify due to consolidation in the industry, thereby
increasing the costs of capitalizing on such opportunities. The Company competes
for acquisition and alliance opportunities with other companies that have
significantly greater financial and management resources. There can be no
assurance that the Company will be successful in acquiring or aligning with any
complementary products, technologies or businesses; or, if acquired or aligned
with, that the Company will be able to successfully integrate any such products,
technologies or businesses into its current business and operations. The failure
to successfully integrate any significant products, technologies or businesses
could have a material adverse effect on the Company's results of operations,
financial condition or business.

Integrating the operations and management of the Company and PHAMIS
has been and will continue to be a time-consuming process, and will require the
dedication of management resources, which has and may continue to temporarily
distract attention from the day-to-day business of the combined Company. There
can be no assurance that this integration will be completed smoothly or
successfully, and the inability of management to successfully integrate the
operations or management of the two companies could have a material adverse
effect on the business, results of operations or financial condition of the
combined Company. As previously discussed in the section "Merger and Related
Costs" the Company has incurred significant merger and related costs. See also
Note 2 to the Notes to Consolidated Financial Statements. Additional
unanticipated expenses may be incurred in connection with the continued
integration of the business of the Company and PHAMIS.

The stock market has, from time to time, experienced extreme price and
volume fluctuations, particularly in the high technology and healthcare
information technology sectors, which have often been unrelated to the operating
performance of particular companies. The Company experiences fluctuations in its
stock price related to these general market swings as well as announcements of
technological innovations, new product introductions by the Company or its
competitors, market conditions in the computer software or hardware industries
and healthcare reform measures. These fluctuations could have a significant
impact on the future market price of the Company's Common Stock.

As a developer of information systems, the Company must anticipate and
adapt to evolving industry standards and new technological developments. The
market for the Company's products is characterized by continued and rapid
technological advances in both hardware and software development, requiring
ongoing expenditures for research and development and the timely introduction of
new products and enhancements to existing products. The establishment of
standards is largely a function of user acceptance. Therefore, such standards
are subject to change. The Company's future success will depend in part upon its
ability to enhance its existing products, to respond effectively to technology
changes, to migrate its clients to new technologies, to sell additional products
to its existing client base and to introduce new products and technologies to
meet the evolving needs of its clients in the healthcare information systems
market. The Company is currently devoting significant resources toward the
development of enhancements to its existing products and the migration of
existing products to new hardware and software platforms. There can be no
assurance that the Company will successfully complete the development of these
products or this migration in a timely fashion or that the Company's current or
future products will satisfy the needs of the healthcare information systems
market. Further, there can be no assurance that products or technologies
developed by others will not adversely affect the Company's competitive position
or render its products or technologies noncompetitive or obsolete.

Any of the Company's internal use systems and any of the products
supplied by the Company to its customers could fail to adequately or properly
process, display, report, or otherwise handle date data containing the year 2000
and beyond. Any failure of a customer to be ready or able to timely install year
2000 ready versions of the Company's products could cause significant
operational problems for the customer. Further, a failure of the Company to
timely make available year 2000 ready versions of its products, or a failure of
the Company to timely provide adequate resources to assist its customers in
installing year 2000 ready versions of its products, could result in claims by
customers, which may have a material adverse effect on the business, operations,
and future financial results of the Company.

The Company currently derives a significant percentage of its revenues
from sales of financial and administrative healthcare information systems and
related services. As a result, any factor adversely affecting sales of these
products and services could have a material adverse effect on the Company's
results of operations, financial condition or business. Although the Company has
experienced increasing annual sales, revenues associated with existing products
may decline as a result of several factors, including price competition. There
can be no assurance that the Company will continue to be successful in marketing
its current products or any new or enhanced products or maintaining the current
pricing for its existing products.

Certain of the Company's products provide applications that relate to
patient medical histories and treatment plans. Any failure by the Company's
products to provide accurate, secure and timely information could result in
product liability claims against the Company by its clients or their affiliates
or patients. The Company maintains insurance that it believes is adequate to
protect against claims associated with the use of its products, but there can be
no assurance that its insurance coverage would adequately cover any claim
asserted against the Company. A successful claim brought against the Company in
excess of its insurance coverage could have a material adverse effect on the
Company's results of operations, financial condition or business. Even
unsuccessful claims could result in the expenditure of funds in litigation, as
well as diversion of management time and resources. There can be no assurance
that the Company will not be subject to product liability claims, that such
claims will not result in liability in excess of its insurance coverage or that
the Company's insurance will cover such claims or that appropriate insurance
will continue to be available to the Company in the future at commercially
reasonable rates.

The success of the Company is dependent to a significant degree on its
key management, sales and marketing, and technical personnel. The Company
believes that its continued future success will also depend upon its ability to
attract, motivate and retain highly skilled, managerial, sales and marketing,
and technical personnel, including software programmers and systems architects
skilled in the computer languages in which the Company's products operate.
Competition for such personnel in the software and information services
industries is intense. The loss of key personnel, or the inability to hire or
retain qualified personnel, could have a material adverse effect on the
Company's results of operations, financial condition or business. Although the
Company has been successful to date in attracting and retaining skilled
personnel, there can be no assurance that the Company will continue to be
successful in attracting and retaining the personnel it requires to successfully
develop new and enhanced products and to continue to grow and operate
profitably.

The healthcare industry in the United States is subject to changing
political, economic and regulatory influences that may affect the procurement
practices and operations of healthcare organizations. The Company's products are
designed to function within the structure of the healthcare financing and
reimbursement system currently being used in the United States. During the past
several years, the healthcare industry has been subject to increasing levels of
governmental regulation of, among other things, reimbursement rates and certain
capital expenditures. From time to time, certain proposals to reform the
healthcare system have been considered by Congress. These proposals, if enacted,
may increase government involvement in healthcare, lower reimbursement rates and
otherwise change the operating environment for the Company's clients. Healthcare
organizations may react to these proposals and the uncertainty surrounding such
proposals by curtailing or deferring investments, including those for the
Company's products and services. The Company cannot predict with any certainty
what impact, if any, such proposals or healthcare reforms might have on its
results of operations, financial condition or business.

The U.S. Food and Drug Administration (the "FDA") has promulgated a
draft policy for the regulation of certain computer software products as medical
devices under the 1976 Medical Device Amendments to the Federal Food, Drug and
Cosmetic Act (the "FDC Act") and has recently indicated it may modify such draft
policy or create a new policy. To the extent that computer software is a medical
device under the policy, the manufacturers of such products could be required,
depending on the product, to (i) register and list their products with the FDA,
(ii) notify the FDA and demonstrate substantial equivalence to other products on
the market before marketing such products, or (iii) obtain FDA approval by
demonstrating safety and effectiveness before marketing a product. Depending
upon the intended use of a device, IDX could be required by the FDA to obtain
extensive data from clinical studies to demonstrate safety or effectiveness, or
substantial equivalence. If the FDA requires such data, IDX would be required to
obtain approval of an investigational device exemption before undertaking
clinical trials. Clinical trials can take extended periods of time to complete
and there can be no assurance that the FDA will approve or clear a device after
the completion of such trials. In addition, such products would be subject to
FDC Act's general controls, including those relating to good manufacturing
practices and adverse experience reporting. Although it is not possible to
anticipate the final form of the FDA's policy with regard to computer software,
the Company expects that, whether or not the draft is finalized or changed, the
FDA is likely to become increasingly active in regulating computer software that
is intended for use in healthcare settings. The FDA can impose extensive
requirements governing pre- and post-market conditions such as service
investigation, approval, labeling and manufacturing. In addition, the FDA can
impose extensive requirements governing development controls and quality
assurance processes. There can be no assurance that actions taken by the FDA to
regulate computer software products will not have a material adverse effect on
the Company's results of operations, financial condition or business.

Because of these and other factors, past financial performance should
not be considered an indicator of future performance. Investors should not use
historical trends to anticipate future results.

Item 7A. Quantitative and Qualitative Disclosures About Market Risk

Not Applicable.

REPORT OF INDEPENDENT AUDITORS

Board of Directors
IDX Systems Corporation

We have audited the accompanying consolidated balance sheets of IDX Systems
Corporation, its subsidiaries and affiliate as of December 31, 1997 and 1996,
and the related consolidated statements of income, stockholders' equity, and
cash flows for each of the three years in the period ended December 31, 1997.
Our audits also included the financial statement schedule listed in the index at
Item 14(a). These financial statements and schedule are the responsibility of
the Company's management. Our responsibility is to express an opinion on these
financial statements and schedule based on our audits. We did not audit the 1996
and 1995 financial statements of PHAMIS, Inc., a wholly-owned subsidiary, which
statements reflect total assets of $43,747,000 as of December 31, 1996 and total
revenues of $49,300,000 and $47,165,000 for the years ended December 31, 1996
and 1995, respectively. Those statements were audited by other auditors whose
report has been furnished to us, and our opinion, insofar as it relates to data
included for PHAMIS, Inc., is based solely on the report of other auditors.

We conducted our audits in accordance with generally accepted auditing
standards. Those standards require that we plan and perform the audit to obtain
reasonable assurance about whether the financial statements are free of material
misstatement. An audit includes examining, on a test basis, evidence supporting
the amounts and disclosures in the financial statements. An audit also includes
s assessing the accounting principles used and significant estimates made by
management, as well as evaluating the overall financial statement presentation.
We believe that our audits and the report of other auditors provide a reasonable
basis for our opinion.

In our opinion, based on our audits and the report of other auditors, the
financial statements referred to above present fairly, in all material respects,
the consolidated financial position of IDX Systems Corporation, its subsidiaries
and affiliate at December 31, 1997 and 1996, and the results of their operations
and their cash flows for each of the three years in the period ended December
31, 1997, in conformity with generally accepted accounting principles. Also, in
our opinion, the related financial statement schedule, when considered in
relation to the basic financial statements taken as a whole, presents fairly, in
all material respects, the information set forth therein.

Ernst & Young LLP

Boston, Massachusetts
February 3, 1998

INDEPENDENT AUDITORS' REPORT
- --------------------------------------------------------------------------------

The Board of Directors and Shareholders
PHAMIS, Inc.:

We have audited the consolidated balance sheet of PHAMIS, Inc. and subsidiaries
as of December 31, 1996, and the related consolidated statements of income,
shareholders' equity and cash flows for each of the years in the two-year period
ended December 31, 1996. The financial statements of PHAMIS, Inc. and
subsidiaries are the responsibility of the Company's management. Our
responsibility is to express an opinion on the PHAMIS, Inc. and subsidiaries'
consolidated financial statements based on our audits.

We conducted our audits in accordance with generally accepted auditing
standards. Those standards require that we plan and perform the audit to obtain
reasonable assurance about whether the financial statements are free of material
misstatement. An audit includes examining, on a test basis, evidence supporting
the amounts and disclosures in the financial statements. An audit also includes
assessing the accounting principles used and significant estimates made by
management, as well as evaluating the overall financial statement presentation.
We believe that our audits provide a reasonable basis for our opinion.

In our opinion, the consolidated financial statements referred to above present
fairly, in all material respects, the financial position of PHAMIS, Inc. and
subsidiaries as of December 31, 1996, and the results of their operations and
their cash flows for each of the years in the two-year period ended December 31,
1996 in conformity with generally accepted accounting principles.

KPMG Peat Marwick LLP

Seattle, Washington
January 31, 1997, except for note 14 to the
PHAMIS, Inc. and subsidiaries'
consolidated financial statements,
which is as of March 25, 1997

Item 8. Financial Statements and Supplementary Data

CONSOLIDATED BALANCE SHEETS
(in thousands, except for per share data)

December 31
1997 1996
---------------------

Assets
Current assets:
Cash and cash equivalents......................................................... $ 14,061 $ 12,327
Securities available-for-sale..................................................... 101,826 101,065
Accounts receivable, less allowance of $1,268 in 1997 and $787 in 1996 for
doubtful accounts.............................................................. 66,587 49,115
Refundable income taxes........................................................... 6,080
Prepaid expenses.................................................................. 2,138 2,116
Other current assets.............................................................. 2,342 2,571
Deferred tax asset................................................................ 4,159 2,556
--------- ---------
Total current assets......................................................... 197,193 169,750
Property and equipment:
Equipment and leasehold improvements, net of accumulated depreciation and
amortization................................................................... 20,905 18,078
Real estate, net of accumulated depreciation...................................... 7,372 4,155
--------- ---------
28,277 22,233
Other:
Capitalized software costs, net................................................... 368 5,120
Other assets...................................................................... 6,175 2,984
Deferred tax asset................................................................ 5,305 2,235
--------- ---------
11,848 10,339
--------- ---------
Total assets................................................................. $ 237,318 $ 202,322
========= =========

Liabilities and Stockholders' Equity

Current liabilities:
Accounts payable.................................................................. $ 10,626 $ 10,380
Accrued expenses.................................................................. 20,536 9,892
Federal and state taxes payable................................................... 735
Deferred revenue.................................................................. 21,538 16,541
Note payable and current portion of long-term debt................................ 3,587 302
--------- ---------
Total current liabilities.................................................... 56,287 37,850
Deferred income taxes 1,191
Long-term debt, less current portion................................................... 2,508 2,651
Commitments and contingencies..........................................................
Minority interest...................................................................... 1,919 2,080
Stockholders' equity:
Preferred stock, par value $0.01 per share, 5,000 shares authorized, none issued
Common stock, par value $0.01 per share, 100,000 shares authorized,
issued and Outstanding 26,029 and 25,462 in 1997 and 1996, respectively.............. 260 255
Additional paid-in capital........................................................... 128,658 118,714
Retained earnings.................................................................... 47,550 39,588
--------- ---------
176,468 158,557
Cumulative unrealized gains (losses) on securities available-for-sale................ 136 (7)
--------- ---------
Total stockholders' equity................................................... 176,604 158,550
--------- ---------
Total liabilities and stockholders' equity................................... $ 237,318 $ 202,322
========= =========

See accompanying notes.

CONSOLIDATED STATEMENTS OF INCOME
(in thousands, except for per share data)

Year Ended December 31
--------------------------------
1997 1996 1995
-------- -------- --------

Revenues:
Systems sales........................................ $ 134,499 $ 110,495 $ 94,163
Maintenance and service fees......................... 116,918 96,384 81,122
--------- --------- ---------
Total revenues................................ 251,417 206,879 175,285

Operating expenses:
Cost of sales........................................ 130,424 108,264 96,750
Selling, general and administrative.................. 51,747 45,929 36,072
Research and development............................. 36,312 29,768 23,425
Write-off of acquired research and development costs 2,290 -- --
Merger and related costs............................. 20,030 292 --
--------- --------- ---------
Total operating expenses................. 240,803 184,253 156,247
--------- --------- ---------

Operating income........................................ 10,614 22,626 19,038
Other (income) expense:
Interest income...................................... (6,322) (5,532) (3,497)
Interest expense..................................... 197 220 263
Minority interest.................................... 539 430 369
--------- --------- ---------
(5,586) (4,882) (2,865)
--------- --------- ---------

Income before income taxes.............................. 16,200 27,508 21,903
Income tax provision (benefit):
Current year operations.............................. 8,238 10,848 3,266
Change in tax status................................. (2,036)
--------- --------- ---------
8,238 10,848 1,230
--------- --------- ---------
Net income.............................................. $ 7,962 $ 16,660 $ 20,673
========= ========= =========
Basic net income per share.............................. $ 0.31 $ 0.66
========= =========
Basic weighted average shares outstanding............... 25,672 25,146
========= =========
Diluted net income per share............................ $ 0.30 $ 0.64
========= =========
Diluted weighted average shares outstanding............. 26,447 26,047
========= =========

Pro forma information (unaudited):
Historical income before income taxes................ $ 21,903
Pro forma income taxes............................... 7,988
---------
Pro forma net income................................. $ 13,915
=========

Pro forma basic net income per share................. $ 0.73
---------
Pro forma basic weighted average shares outstanding.. 19,135
=========

Pro forma diluted net income per share.............. $ 0.63
---------
Pro forma diluted weighted average shares outstanding 22,158
=========

See accompanying notes.

CONSOLIDATED STATEMENTS OF STOCKHOLDERS' EQUITY
(in thousands)

- -----------------------------------------------------------------------------------------------------------------------
Common Stock Treasury Stock
- -----------------------------------------------------------------------------------------------------------------------
Unrealized
Gain
(Loss) on
Additional Securities Total
Par Paid-in Retained Available- Stockholders'
Shares Value Capital Earnings Shares Cost for-Sale Equity
- -----------------------------------------------------------------------------------------------------------------------

Balances at December 31, 1994 18,369 $ 184 $ 20,324 $41,047 615 $ (393) $ (264) $ 60,898
- -----------------------------------------------------------------------------------------------------------------------
S Corporation distribution (38,792) (38,792)
- -----------------------------------------------------------------------------------------------------------------------
Stock issued upon exercise 1,021 10 2,963 (615) 393 3,366
of nonqualified stock options
- -----------------------------------------------------------------------------------------------------------------------
Tax benefit related to 956 956
exercise of nonqualified
stock options
- -----------------------------------------------------------------------------------------------------------------------
Stock issued upon exercise of 394 4 2,051 2,055
incentive stock options
- -----------------------------------------------------------------------------------------------------------------------
Stock issued pursuant to 5 149 149
employee stock purchase plan
- -----------------------------------------------------------------------------------------------------------------------
Stock issued to 401(k) plan 18 520 520
- -----------------------------------------------------------------------------------------------------------------------
Stock issued upon initial 4,886 49 80,292 80,341
public offerings, net of
offering costs of $7,172
- -----------------------------------------------------------------------------------------------------------------------
Change in unrealized gain 345 345
(loss) on securities
available-for-sale
- -----------------------------------------------------------------------------------------------------------------------
Net income 20,673 20,673
- -----------------------------------------------------------------------------------------------------------------------
Balances at December 31, 1995 24,693 247 107,255 22,928 0 0 81 130,511
- -----------------------------------------------------------------------------------------------------------------------
Stock issued upon exercise of 8 56 56
nonqualified stock options
- -----------------------------------------------------------------------------------------------------------------------
Tax benefit related to 4,812 4,812
exercise of nonqualified stock
options
- -----------------------------------------------------------------------------------------------------------------------
Stock issued upon exercise of 569 6 3,037 3,043
incentive stock options
- -----------------------------------------------------------------------------------------------------------------------
Stock issued pursuant to 171 2 3,090 3,092
employee stock purchase plan
- -----------------------------------------------------------------------------------------------------------------------
Stock issued to 401(k) plan 21 464 464
- -----------------------------------------------------------------------------------------------------------------------
Change in unrealized gain (88) (88)
(loss) on securities
available-for-sale
- -----------------------------------------------------------------------------------------------------------------------
Net income 16,660 16,660
- -----------------------------------------------------------------------------------------------------------------------
Balances at December 31, 1996 25,462 255 118,714 39,588 0 0 (7) 158,550
- -----------------------------------------------------------------------------------------------------------------------
Stock issued upon exercise of 73 1 1,153 1,154
nonqualified stock options
- -----------------------------------------------------------------------------------------------------------------------
Tax benefit related to 3,059 3,059
exercise of nonqualified
stock options
- -----------------------------------------------------------------------------------------------------------------------
Stock issued upon exercise of 419 4 3,887 3,891
incentive stock options
- -----------------------------------------------------------------------------------------------------------------------
Stock issued pursuant to 54 1,408 1,408
employee stock purchase plan
- -----------------------------------------------------------------------------------------------------------------------
Stock issued to 401(k) plan 21 437 437
- -----------------------------------------------------------------------------------------------------------------------
Change in unrealized gain
(loss) on securities
available-for-sale 143 143
- -----------------------------------------------------------------------------------------------------------------------
Net income 7,962 7,962
- -----------------------------------------------------------------------------------------------------------------------
Balances at December 31, 1997 26,029 $ 260 $ 128,658 $47,550 0 $ 0 $ 136 $176,604
=======================================================================================================================

See accompanying notes.

CONSOLIDATED STATEMENTS OF CASH FLOWS
(in thousands)

Year Ended December 31
------------------------------
1997 1996 1995
-------- -------- --------

Operating Activities
Net income................................................................ $ 7,962 $ 16,660 $ 20,673
Adjustments to reconcile net income to net cash provided by operating
activities:
Depreciation of property and equipment............................... 8,066 5,990 5,875
Amortization of capitalized software................................. 806 1,337 943
Deferred tax benefit................................................. (5,864) (1,664) (1,679)
Provision for doubtful accounts...................................... 593 360 387
Minority interest.................................................... 539 430 369
Write-off of acquired in-process research and development costs...... 2,290
Write-off of capitalized software costs and equipment in connection
with merger........................................................ 7,406
Changes in operating assets and liabilities:
Accounts receivable............................................. (18,065) (14,633) (11,718)
Prepaid expenses and other assets............................... (2,984) (2,596) (570)
Accounts payable................................................ 246 2,576 2,748
Accrued expenses................................................ 10,644 545 3,542
Federal and state taxes payable................................. (6,815) (71) 46
Deferred revenue................................................ 4,997 1,539 1,041
-------- -------- --------
Net cash provided by operating activities................................. 9,821 10,473 21,657

Investing Activities
Purchase of property and equipment, net................................... (15,711) (8,891) (7,114)
Purchase of securities available-for-sale................................. (151,537) (147,056) (102,382)
Proceeds from sale of securities available-for-sale ...................... 150,919 112,297 56,989
Purchase of data model technology......................................... (2,500)
Capitalized software development costs.................................... (1,649) (3,397) (2,796)
-------- -------- --------
Net cash used in investing activities..................................... (20,478) (47,047) (55,303)

Financing Activities
Proceeds from sale of common stock........................................ 6,890 6,655 6,090
Tax benefit related to exercise of non qualified stock options............ 3,059 4,812 956
Proceeds from initial public offerings, net............................... 80,340
S Corporation distribution................................................ (38,792)
Contributions to (distributions from) Affiliates.......................... (700) 467 (225)
Proceeds from note payable................................................ 3,350
Repayment of notes receivable from related parties........................ 13,638
Proceeds from (repayment of) note payable to bank......................... (209) 109
Repayment of long-term debt............................................... (208) (574) (856)
-------- -------- --------
Net cash provided by financing activities................................. 12,391 11,151 61,260
-------- -------- --------
Increase (decrease) in cash and cash equivalents.......................... 1,734 (25,423) 27,614
Cash and cash equivalents at beginning of year............................ 12,327 37,750 10,136
-------- -------- --------
Cash and cash equivalents at end of year.................................. $ 14,061 $ 12,327 $ 37,750
======== ======== ========
Supplemental Cash Flow Information
Cash paid for interest.................................................... $ 190 $ 158 $ 283
======== ======== ========
Cash paid for income taxes................................................ $ 17,382 $ 8,321 $ 1,654
======== ======== ========

See accompanying notes.

IDX SYSTEMS CORPORATION

NOTES TO CONSOLIDATED FINANCIAL STATEMENTS
December 31, 1997

1. Significant Accounting Policies

Nature of Business

IDX Systems Corporation (IDX or the Company) operates in one principal
industry segment providing healthcare information systems and services
principally in the United States. Revenues are derived from the licensing of
software, maintenance and services related to systems sales.

In July 1997, IDX completed its merger (Merger) with PHAMIS, Inc. (PHAMIS)
in a stock for stock transaction. The transaction, which was accounted for as a
pooling-of-interests, was effected through the exchange of .73 shares of IDX
common stock in exchange for each PHAMIS share outstanding. Approximately 4.6
million shares of common stock were issued in connection with the Merger. PHAMIS
was a Seattle-based provider of enterprise-wide, patient-centered healthcare
information systems.

The consolidated financial statements for all periods prior to the Merger
have been restated to include the accounts and results of operations of PHAMIS.
No adjustments were required to conform the financial reporting policies of IDX
and PHAMIS for the periods presented.

Basis of Presentation and Principles of Consolidation

The consolidated financial statements include the accounts of the Company,
its subsidiaries and a real estate trust. Investments in entities, representing
an ownership interest of less than 20%, are accounted for under the cost method.

The Company leases a substantial portion of its space, including its
corporate headquarters and certain sales and support offices, from real estate
partnerships and trusts owned by stockholders and certain key employees of the
Company. These real estate partnerships and trusts include 116 Huntington Avenue
Limited Partnership ("HLP"), BDP Realty Associates ("BDP") and other real estate
partnerships and trusts ("REPs"). The Company's consolidated financial
statements include the accounts of the Company and BDP whose real estate is
leased exclusively by the Company and for which the Company is subject to
substantially all the risks of ownership. Real estate owned by HLP and REPs are
leased to the Company under operating leases. All transactions between the
Company and BDP are eliminated. Minority interest represents net income and
equity of BDP.

Revenue Recognition

Software License Fees

The Company recognizes revenue in accordance with the provisions of AICPA
Statement of Position No. 91-1 "Software Revenue Recognition" (SOP 91-1).
Software license fees, which are based upon vendor-specific objective
information, represent revenues derived from the license of the Company's
proprietary systems software which generally requires no significant production,
modification or customization. IDX license revenue is deferred and recognized as
customer payments become due based upon specified milestones and due dates
including delivery, installation and final systems acceptance. PHAMIS license
revenues are principally recognized using the percentage-of-completion method as
systems customization progresses. These revenues are measured primarily based on
the ratio of labor incurred to total estimated labor to complete each contract,
as prescribed by generally accepted accounting principles for long-term, fixed-
price contracts. If the total estimated cost of a contract is expected to exceed
the contract price, the total estimated loss is recognized in the period in
which such loss is determined.

Hardware Sales

Revenue from sale of computer equipment related to IDX contracts is
recognized upon shipment, provided post-sale vendor obligations are
insignificant and the sales value is based on vendor-specific objective
information. If post-sale vendor obligations are significant, revenue is
deferred until the obligations are fulfilled. Revenue from the sale of hardware
related to PHAMIS contracts is principally recognized using the percentage-of-
completion method as systems customization progresses. Revenue from the sale of
PHAMIS hardware not included in a systems contract is recognized upon shipment.

Maintenance and Services

IDX installation service revenue related to systems sales, which is based
on vendor-specific objective information, is recognized upon fulfillment of
contractual obligations based upon achievement of specified milestones. PHAMIS
installation service revenue is recognized using the percentage-of-completion
method as systems customization progresses. Professional service revenue is
recognized as the services are performed. Maintenance is recognized ratably over
the term of the agreement.

Due to the elimination of providing customized systems software, the
Company is recognizing revenues derived from license fees, hardware sales and
services related to PHAMIS system software contracts entered into after the
Merger, on the same basis as IDX.

Statement of Position 97-2

During 1997, the AICPA issued Statement of Position 97-2 "Software Revenue
Recognition" (SOP 97-2). SOP 97-2 provides guidance on applying generally
accepted accounting principles in recognizing revenue on software transactions.
SOP 97-2 is effective for transactions entered into in fiscal years beginning
after December 15, 1997. The Company does not expect adoption will materially
affect its revenue recognition policies with respect to revenue derived from
systems sales and services since each element of revenue is based upon
vendor-specific objective information, systems software requires no significant
production, modification or customization and revenues are recognized as
customer payments become due based upon milestones and due dates including
delivery, installation and final systems acceptance.

Accounting Pronouncements

In June 1997, the Financial Accounting Standards Board issued SFAS No. 130,
"Reporting Comprehensive Income" and SFAS No. 131, "Disclosures About Segments
of an Enterprise and Related Information." Both SFAS No. 130 and SFAS No. 131
are effective for fiscal years beginning after December 15, 1997. The Company
believes that the adoption of these new accounting standards will not have a
material impact on the Company's financial statements.

Research and Development Costs

Research and development costs are expensed as incurred. Software
development costs incurred after the establishment of technological feasibility
and until the product is available for general release are capitalized, provided
recoverability is reasonably assured. Technological feasibility is established
upon the completion of a working model. Software development costs, when
material, are stated at the lower of unamortized cost or net realizable value.
Net realizable value for each software product is assessed based on anticipated
profitability applicable to sales of the related product in future periods.
Amortization of capitalized software costs begins when the related product is
available for general release to customers and is provided for each product
based on the greater of the amount computed using (i) the ratio of current gross
revenues to total current and anticipated future gross revenues for the related
software or (ii) the straight-line method over a three-year life or the
product's estimated economic life, if shorter. Capitalized software development
costs of $368,000 and $5,120,000 at December 31, 1997 and 1996, respectively,
net of accumulated amortization, are included in other assets in the
accompanying balance sheets. Amortization of capitalized software amounted to
$806,000, $1,337,000 and $943,000 in 1997, 1996 and 1995, respectively. In
connection with the Merger, the Company wrote-off $5.6 million of capitalized
software development costs attributable to the elimination of overlapping
products.

Cash Equivalents

The Company considers highly liquid investments generally with a maturity
of three months or less when purchased, to be cash equivalents. Cash equivalents
are stated at cost, which approximates market value.

Risks and Uncertainties

Concentration of Credit Risk

Financial instruments which potentially subject the Company to a
concentration of credit risk principally consist of cash and cash equivalents,
securities available-for-sale and trade receivables.

The Company invests excess cash primarily in money market mutual funds and
tax exempt municipal funds with high credit ratings, debt securities with highly
rated issuers and treasury notes and bonds issued by the United States
Government and the State of Vermont.

The Company's customers are substantially all large integrated healthcare
delivery enterprises principally located in the United States. To reduce credit
risk, the Company performs ongoing credit evaluations of the financial condition
of its customers. Although the Company is directly affected by the overall
financial condition of the healthcare industry, management does not believe
significant credit risk exists at December 31, 1997. The Company's losses
related to collection of trade accounts receivables have consistently been
within management's expectations.

Significant Estimates and Assumptions

The preparation of financial statements in conformity with generally
accepted accounting principles requires management to make significant estimates
and assumptions that affect the reported amounts of assets and liabilities and
disclosure of contingent assets and liabilities at the date of the financial
statements and the reported amounts of revenues and expenses during the
reporting period. Significant estimates and assumptions by management affect the
Company's allowance for doubtful accounts, revenue recognition and certain
accrued expenses. Actual results could differ from those estimates.

Investment Securities

The Company accounts for investment securities based on Statement of
Financial Accounting Standards No. 115, "Accounting for Certain Investments in
Debt and Equity Securities" ("SFAS No. 115"). SFAS No. 115 provides the
accounting and reporting requirements for investments in securities that have
readily determinable fair values and for all investments in debt securities. All
of the Company's investments have been classified as available-for-sale
securities at December 31, 1997 and 1996. Available-for-sale securities are
carried at fair value with unrealized gains and losses reported as a component
of stockholders' equity.

Property and Equipment

Real estate, which includes land, buildings and related improvements owned
by BDP, is stated at cost. Buildings and related improvements are depreciated
using the straight-line method over their estimated useful lives of 30 to 40
years.

Equipment is stated at cost and is depreciated over its estimated useful
life by using the straight-line method. Equipment under capital leases is stated
at the lower of the present value of minimum lease payments discounted at the
Company's incremental borrowing rate at the beginning of the lease term or fair
value at the inception of the lease. Depreciation is generally computed based on
useful lives of three to five years for computer equipment and software and five
to ten years for furniture and fixtures. Leasehold improvements are amortized
using the straight-line method over the lesser of the term of the respective
lease or the estimated useful life of the asset.

Income Taxes

On November 1, 1995, the Company terminated its status as an "S
Corporation" under Section 1362 of the Internal Revenue Code, and thereafter has
become subject to federal and state corporate income taxes. Prior to November 1,
1995, the Company was not liable for federal income taxes as income was taxed
directly to the Company's stockholders. The Company had provided for income
taxes in states in which it operated that did not recognize "S Corporation"
status. This change in tax status resulted in the Company recognizing a
$2,036,000 tax benefit in 1995.

The Company accounts for income taxes using the liability method as
required by SFAS No. 109, "Accounting for Income Taxes." Under this method,
deferred income taxes are recognized for the future tax consequences of
differences between the tax and financial accounting of assets and liabilities
at each year end. Deferred income taxes are based on enacted tax laws and
statutory tax rates applicable to the periods in which the differences are
expected to affect taxable income. A valuation allowance is established when
necessary to reduce deferred tax assets to the amounts expected to be realized.
Income tax expense is the tax payable for the period and the change during the
period in deferred tax assets and liabilities.

Stock Option Plans

The Company grants stock options for a fixed number of shares to employees
with an exercise price equal to the fair value of the shares at the date of the
grant. The Company has elected to follow Accounting Principles Board Opinion No.
25, "Accounting for Stock Issued to Employees" ("APB 25") and related
Interpretations in accounting for its employee stock options because the
alternative fair value accounting provided for under SFAS No. 123, "Accounting
for Stock-Based Compensation," requires use of option valuation models that were
not developed for use in valuing employee stock options. Under APB 25, because
the exercise price of the Company's employee stock options equals the market
price of the underlying stock on the date of grant, no compensation expense is
recognized.

Net Income Per Share

Pro Forma Information (Unaudited)

Pro Forma Consolidated Statement of Income

On November 1, 1995, the Company terminated its status as an S Corporation
and thereafter became subject to federal and state corporate income taxes.
Accordingly, for informational purposes, the accompanying consolidated statement
of income for the year ended December 31, 1995 includes an unaudited pro forma
adjustment for income taxes, based on the tax laws in effect at the time, which
would have been recorded if the Company had not been an S Corporation.

Total pro forma income tax expense is different from the amount which would
be provided by applying the statutory federal rate to income before income taxes
principally due to the effect of state income taxes and the reduction of the
valuation allowance which had previously been provided due to the uncertainty of
realization of certain tax benefits during the carryforward period.

Pro Forma Net Income Per Share

Pro forma net income per share is computed using pro forma net income and
the weighted average number of common and dilutive Common Stock equivalent
shares. Common Stock equivalents are attributable to stock options using the
treasury stock method and, for the nine-month period ended September 30, 1995,
include the weighted average estimated number of shares which would be necessary
to fund the payment of undistributed S Corporation earnings in excess of the
previous twelve months net income. Common Stock and Common Stock equivalent
shares issued during the twelve-month period prior to the effective date of the
initial public offering previously required by the Securities and Exchange
Commission (SEC) to be included in the earnings per share calculation have been
excluded and pro forma net income per share restated in connection with the
adoption of SFAS No. 128, pursuant to SEC Staff Accounting Bulletin 98, issued
in February 1998.

Reclassification

Certain amounts in 1996 and 1995 have been reclassified to permit
comparison.

2. Business Combinations

In July 1997, the Company completed the Merger with PHAMIS which became a
wholly-owned subsidiary of the Company. The transaction was accounted for as a
pooling-of-interests and accordingly, the accompanying financial statements
include the accounts of PHAMIS for all periods presented. In connection with the
Merger, the Company incurred approximately $20 million of merger and related
costs consisting principally of transaction costs of $5.1 million, write-offs
and adjustments of $7.4 million of long-lived assets, primarily capitalized
software development costs and equipment due to the elimination of overlapping
products and operations, employee termination and related costs of $2.7 million
and other merger related costs of $4.8 million related to integration costs
incurred during the year and the termination of leases and other contractual
obligations.

At December 31, 1997, accounts payable and accrued expenses include accrued
costs of $3.1 million related to the termination of employees, leases and other
contractual obligations, substantially all of which will be paid within one
year. During 1997 cash paid and charged to the accrual established as of the
date of the Merger related to employee terminations and termination of leases
and other contractual obligations amounted to approximately $1.7 million. The
write-off of long-lived assets is not expected to materially affect amortization
and depreciation of future reporting periods. In addition, the provision for
termination of employees, leases and other contractual obligations is not
expected to materially affect selling, general and administrative expenses or
cash flows of future periods. Management does not expect to incur significant
charges related to the Merger in future reporting periods.

The results of operations previously reported by the separate enterprises
and the consolidated amounts for the years ended December 31, 1996 and 1995 and
the six months ended June 30, 1997 are summarized below.

Six months ended Year ended December 31,
June 30, 1997 1996 1995
---------------------------------------------------------------
(in thousands)

Total revenues:
IDX $ 92,606 $ 157,579 $ 128,120
PHAMIS 24,385 49,300 47,165
---------------------------------------------------------------

Consolidated $ 116,991 $ 206,879 $ 175,285
===============================================================

Net income (loss):
IDX $ 8,417 $ 14,882 $ 16,365
PHAMIS (44) 1,778 4,308
---------------------------------------------------------------

Consolidated $ 8,373 $ 16,660 $ 20,673
===============================================================

In February 1997, the Company acquired certain data model technology from
Medaphis Healthcare Information Technology Company for cash of $2.5 million. The
acquisition was accounted for under the purchase method. Approximately $2.3
million of the purchase price has been expensed as in-process research and
development in connection with the Company's development of a healthcare data
model.

In March 1996, PHAMIS completed its merger with DataBreeze, Inc.
(DataBreeze) in a stock for stock transaction. Approximately 154,000 shares of
Common Stock were issued in connection with the DataBreeze merger, which was
accounted for as a pooling-of-interests. DataBreeze is a Florida based provider
of information systems for the physician practice management marketplace. The
restatement of the consolidated financial statements of PHAMIS to include the
accounts and results of operations of DataBreeze for periods prior to the merger
did not materially affect the Company's consolidated financial statements.

3. Securities Available-for-Sale

The following is a summary of securities available-for-sale at December 31,
1997 and 1996:

Gross Gross Estimated
----- ----- ---------
Unrealized Unrealized Fair
---------- ---------- ----
Cost Gains Losses Value
------------- ----- ------ -----
(in thousands)

December 31, 1997
U.S. government securities..... $ 31,292 $ 75 $ (8) $ 31,359
Other debt securities.......... 10,995 33 (6) 11,022
--------------------------------------------------
Total debt securities..... 42,287 108 (14) 42,381
Tax-deferred municipal funds... 25,181 46 (4) 25,223
Money market fund.............. 34,222 34,222
--------------------------------------------------
$101,690 $154 $(18) $101,826
==================================================

December 31, 1996
U.S. government securities..... $ 56,887 $ 60 $(57) $ 56,890
Other debt securities.......... 1,563 1 (11) 1,553
--------------------------------------------------
Total debt securities..... 58,450 61 (68) 58,443
Tax-deferred municipal funds... 8,500 8,500
Tax-free investment fund....... 34,122 34,122
--------------------------------------------------
$101,072 $ 61 $(68) $101,065
==================================================

The net unrealized gain (loss) on securities available-for-sale included as
a separate component of stockholders' equity totaled $136,000 and $(7,000) at
December 31, 1997 and 1996, respectively.

The amortized cost and estimated fair value of debt securities at December
31, 1997, by contractual maturity, are shown below.

Estimated
---------
Cost Fair Value
-------- ----------
(in thousands)
Due in one year or less................... $25,626 $25,641
Due after one year through three years.... 11,447 11,534
Due after three years..................... 5,214 5,206
---------------------------
$42,287 $42,381
===========================

4. Advances to Related Parties

Prior to 1996, the Company advanced $2,670,000 to HLP which was used in
connection with the construction of leasehold improvements to be owned by the
Company. At December 31, 1995, leasehold improvements of $1,509,000 were
capitalized by the Company and the balance of the advance of $1,161,000 was
remitted to the Company.

5. Equipment and Leasehold Improvements

Equipment and leasehold improvements consists of the following:

December 31
--------------

1997 1996
------- --------
(in thousands)
Computer equipment and software..................... $32,954 $26,692
Furniture and fixtures.............................. 6,567 6,025
Leasehold improvements.............................. 7,334 7,176
----- -----
46,855 39,893
Less accumulated depreciation and amortization...... 25,950 21,815
------ ------
$20,905 $18,078
======= =======

6. Other Investments and Advances

In February 1996, PHAMIS signed a Distribution Agreement (the Agreement)
with a California-based software developer of mobile computing solutions for the
home healthcare marketplace. The Agreement allows PHAMIS to distribute the home
healthcare solutions throughout its direct sales network. In addition to the
Agreement, PHAMIS purchased a minority equity interest in the developer for
approximately $950,000 in cash. The equity interest is accounted for under the
cost method of accounting.

In December 1995, PHAMIS purchased an equity interest in a critical care
information systems developer based in Europe for approximately $1,082,000 in
cash. The equity interest is accounted for under the cost method of accounting.
In addition to the equity interest, PHAMIS entered into an OEM Distribution
Agreement (the OEM Agreement) to distribute the critical care system throughout
its customer base. In connection with the OEM Agreement, PHAMIS paid certain
costs for advance license fees, which are recorded as prepaid expenses. During
1996, PHAMIS invested an additional $225,000 in connection with an additional
round of equity financing by the developer.

7. Accrued Expenses

Accrued expenses consist of the following:

December 31,
1997 1996
-------------------------------------
(in thousands)

Employee compensation and benefits $12,653 $6,761
Merger related costs 3,098
Other 4,785 3,131
-------------------------------------
$20,536 $9,892
=====================================

8. Financing Arrangements

Under a line of credit arrangement with a bank, the Company may borrow up
to $5,000,000 on a demand basis subject to terms and conditions upon which the
Company and the bank may mutually agree. The line of credit arrangement expires
on May 31, 1998. At December 31, 1997 and for each of the three years in the
period then ended, there were no borrowings under this arrangement.

BDP had a $4,000,000 demand line of credit agreement with a bank, under
which borrowings of $3,350,000, bearing interest of 7.4%, were outstanding at
December 31, 1997. These borrowings were repaid in January 1998. The carrying
amount approximates fair value due to the short-term maturity of the agreement.

PHAMIS had an unsecured $5,000,000 revolving line of credit agreement with
a bank which was canceled in connection with the Merger. There were no amounts
outstanding at December 31, 1996.

Long-term debt, principally related to certain real estate described
below, is as follows:

December 31
-----------

1997 1996
---- ----
(in thousands)

Obligation under industrial revenue bond, principal
installments of $200, interest at a floating
variable rate (4.45% at December 31, 1997),
secured by real estate owned by BDP............... $2,700 $2,800
Other.............................................. 45 153
-------------------
2,745 2,953
Less current portion............................... 237 302
-------------------
Long-term debt..................................... $2,508 $2,651
===================

The industrial revenue bond and related mortgage notes payable are
collateralized by land and buildings consisting of the Company's corporate
headquarters owned by BDP whose real estate was leased exclusively by the
Company and for which the Company is subject to substantially all the risks of
ownership. These obligations require BDP to maintain certain financial ratios
and comply with certain covenants. These borrowings were repaid in February
1998. The carrying amount of long-term debt approximates fair value due to the
variable rate of interest.

At December 31, 1997 and 1996, real estate owned by BDP and financed by the
obligation indicated above consisted of the following:

December 31
-----------
1997 1996
------ ------
(in thousands)
Corporate headquarters........ $8,794 $5,438
Accumulated depreciation...... 1,422 1,283
------ ------
$7,372 $4,155
====== ======

Operating Leases

The Company leases approximately 47% of the office space in a commercial
office building owned by HLP (see Note 4). HLP is owned and controlled by
stockholders and certain key employees of the Company. At December 31, 1997,
future obligations due under the operating lease with HLP, REPs and unrelated
parties for sales and support offices are as follows:

Unrelated
HLP REPs Sub Total Parties Total
------- ------ --------- ------- -----
(in thousands)

Year ending December 31:
1998..................... $ 2,710 $ 295 $ 3,005 $ 5,025 $ 8,030
1999..................... 2,710 251 2,961 4,354 7,315
2000..................... 2,920 251 3,171 3,632 6,803
2001..................... 2,920 251 3,171 3,612 6,783
2002..................... 2,920 105 3,025 3,391 6,416
Thereafter............... 33,870 33,870 12,707 46,577
---------------------------------------------------
$48,050 $1,153 $49,203 $32,721 $81,924
===================================================

Total rent expense amounted to $6,906,000, $5,563,000 and $5,278,000,
during 1997, 1996 and 1995, respectively. Total rent expense includes
$3,024,000, $2,621,000 and $2,571,000 in 1997, 1996 and 1995, respectively,
related to the lease with HLP. Total rent expense includes $448,000, $381,000
and $915,000 in 1997, 1996 and 1995, respectively, related to the leases with
REPs.

9. Income Taxes

The provision for income taxes consists of the following:

1997 1996 1995
---------- --------- ---------
(in thousands)
Currently payable:
Federal..................... $11,282 $10,317 $2,497
State....................... 2,820 2,195 412
------- ------- ------
14,102 12,512 2,909
Deferred, principally Federal.... (5,864) (1,664) (1,679)
------- ------- ------
$ 8,238 $10,848 $1,230
======= ======= ======

A reconciliation of the federal statutory rate to the effective income tax
rate during 1997, 1996 and 1995 is as follows:

1997 1996 1995
-------- -------- --------

Tax at federal statutory rate........ 35.0% 35.0% 35.0%
State taxes, net of federal benefit. 5.5 5.2 5.2
Non-deductible costs of merger....... 10.4 (.2)
Change in tax status................. (34.6)
Other, net........................... (.6)
-------------------------------
50.9% 39.4% 5.6%
===============================

Significant components of the Company's deferred tax assets (liabilities)
are as follows:

1997 1996
----------------------
(In thousands)

Deferred tax assets:
Allowances and accruals $6,248 $ 1,628
Depreciation 2,049 2,235
Research and development tax credit 244
Loss carryforwards and other tax credits 600 1,121
Deferred revenue 1,314 937
Other 68
----------------------
Total deferred tax assets 10,211 6,233
----------------------
Deferred tax liabilities:
Capitalized software costs, net of accumulated amortization 147 1,888
Other 145
----------------------
Total deferred tax liabilities 147 2,033
----------------------
Net deferred tax asset 10,064 4,200

Less valuation allowance 600 600
----------------------
$9,464 $ 3,600
----------------------

Deferred income taxes are included in accompanying balance
sheets under the following captions:
Current assets $4,159 $ 2,556
Noncurrent assets 5,305 2,235
Noncurrent liabilities (1,191)
----------------------
$9,464 $ 3,600
======================

10. Net Income Per Share

The following sets forth the computation of basic and diluted earnings per
share:

1997 1996
-------------------------

Numerator:
Net income $ 7,962 $16,660
-------------------------
Numerator for basic and diluted earnings per share $ 7,962 $16,660

Denominator:
Denominator for basic earnings per share--
weighted-average share 25,672 25,146
Effect of employee stock options 775 901
-------------------------
Denominator for diluted earnings per share 26,447 26,047
=========================
Basic earnings per share $ 0.31 $ 0.66
=========================
Diluted earnings per share $ 0.30 $ 0.64
=========================

11. Recapitalization and Initial Public Offerings

In July 1997, IDX's Board of Directors and stockholders approved an
amendment to its charter to increase the number of authorized shares of Common
Stock to 100,000,000.

In November 1995, IDX completed its initial public offering in which
4,604,500 shares of Common Stock were sold at a per share price of $18. Net
proceeds, after deduction of $6,717,000 for underwriters' fees and other
offering costs, amounted to $76,164,000.

In September 1995, IDX's Board of Directors and stockholders approved a
four-for-one stock split of its Common Stock, effective September 27, 1995. All
shares and option information in the accompanying consolidated financial
statements have been retroactively adjusted to reflect the stock split.

In September 1995, IDX's Board of Directors and stockholders approved an
amendment to its charter to authorize 5,000,000 shares of undesignated preferred
stock, and increase the number of authorized shares of Common Stock to
50,000,000. These amendments became effective on November 17, 1995.

In January 1995, 281,000 shares of PHAMIS Common Stock were issued to cover
underwriters' overallotments made in connection with its IPO completed in 1994.
Net proceeds, after deduction of $455,400 for underwriters' fees and other
offering costs, amounted to $4,177,000.

12. Benefit Plans

Retirement Plans

Profit Sharing Retirement Plan

The Company maintains a profit sharing retirement plan for all IDX
employees meeting age and service requirements. PHAMIS employees are not
eligible for the profit sharing retirement plan due to their eligibility in the
PHAMIS 401(k) plan described below. The contributions to the plan are
discretionary, as determined by the Board of Directors. The Company expects to
continue the plan indefinitely; however, IDX has reserved the right to modify,
amend or terminate the plan. For the years ended December 31, 1997, 1996 and
1995, the Company has expensed $4,316,000, $2,840,000 and $2,400,000,
respectively.

401(k) Retirement Savings Plan

The Company maintains a 401(k) retirement savings plan for which all PHAMIS
full-time employees are eligible to participate. Participants become eligible
for the employer-matching contribution on the first day of the calendar quarter
immediately following the completion of one year of service. Prior to the
Merger, the Company matched 50% of participant contributions up to a maximum
contribution of $1,500 per employee in company stock. The 401(k) retirement
savings plan was amended in July 1997 to provide for the Company match to be
made in cash. Matching contributions to the plan were $357,000, $320,000 and
$165,000 in the years ended December 31, 1997, 1996 and 1995, respectively. A
total of 240,000 shares of Common Stock have been reserved for issuance under
the 401(k) retirement savings plan.

Stock Purchase Plans

In September 1995, IDX's Board of Directors and stockholders approved the
1995 Employee Stock Purchase Plan, as amended in July 1997, (the "ESPP") under
which eligible employees may purchase Common Stock at a price per share equal to
85% of the lower of the fair market value of the Common Stock at the beginning
or end of each offering period. Participation in the offering is limited to 10%
of an employee's compensation (not to exceed amounts allowed under Section 423
of the Internal Revenue Code), may be terminated at any time by the employee and
automatically ends on termination of employment with the Company. A total of
1,400,000 shares of Common Stock have been reserved for issuance under this
plan.

PHAMIS maintained an employee stock purchase plan prior to the Merger
whereby eligible employees could purchase PHAMIS Common Stock at 85% of the
lower of the fair market value of the Common Stock at the beginning or end of
each offering period. The employee stock purchase plan was terminated in
connection with the Merger.

During the years ended December 31, 1997, 1996 and 1995, an aggregate of
approximately 54,000, 171,000 and 5,000 shares, respectively, were purchased
under these stock purchase plans.

Stock Option Plans

IDX Option Plans

During 1985 and 1994, the Company established incentive stock option plans
providing for the grant of options for the issuance of 959,640 and 696,460
shares, respectively, of Common Stock. Options were granted at fair market value
at the time of grant and became immediately exercisable at the time of the
initial public offering. The options expire on the tenth anniversary of the date
of the grant or upon termination of employment. The 1994 Plan was terminated
upon the completion of the initial public offering. The 1985 Plan was terminated
for purposes of prospective eligibility in March 1995. At December 31, 1997,
options to purchase 70,600 and 211,845 shares of Common Stock were outstanding
and exercisable under the 1994 Plan and the 1985 Plan, respectively.

In September 1995, the Company's stockholders approved the 1995 Stock
Option Plan as amended in July 1997, (the "1995 Option Plan"). The 1995 Option
Plan provides for the grant of stock options to employees, officers and
directors of, and consultants or advisors to, the Company. Under the 1995 Option
Plan, the Company may grant options that are intended to qualify as incentive
stock options under provisions of the Internal Revenue Code or options not
intended to qualify as incentive stock options. The option grants, exercise
price, vesting and expiration are authorized by a compensation committee
comprised of certain of the Company's directors. A total of 4,500,000 shares of
Common Stock may be issued upon the exercise of options granted under the 1995
Option Plan. At December 31, 1997, options to purchase 1,515,064 shares of
Common Stock were outstanding under the 1995 Option Plan, of which 246,604 were
exercisable.

Prior to adoption of the 1995 Option Plan, nonqualified stock options were
granted under separate option agreements at a minimum of the fair market value
at the date of grant, and generally vested over five years or immediately in the
event of a merger of the Company when the Company is not the surviving entity.
At December 31, 1997, there were no options outstanding under such agreements.

In September 1995, IDX's Board of Directors approved the 1995 Director
Stock Option Plan as amended in May and July 1997, (the "IDX Director Plan"),
which provides that each non-employee director of the Company be granted an
option to acquire 2,000 shares of Common Stock on the date that person becomes a
director but, in any event, not earlier than the effective date of the IDX
Director Plan. Options are granted at a price equal to the fair market value on
the date of grant. The option becomes exercisable on the first anniversary of
the date of grant, and the term of the option is ten years from the date of
grant. The Company has reserved 80,000 shares of Common Stock for issuance under
the IDX Director Plan. At December 31, 1997, options to purchase 17,394 shares
of Common Stock were outstanding under the IDX Director Plan of which 12,000
where exercisable.

PHAMIS Stock Option Plans

Options to purchase shares of PHAMIS Common Stock under the PHAMIS, Inc.
Amended and Restated 1983 Combined Nonqualified and Incentive Stock Option Plan
(the "1983 Option Plan"), the PHAMIS, Inc. 1993 Combined Incentive and
Nonqualified Stock Option Plan (the "1993 Option Plan") and the PHAMIS, Inc.
1994 Nonemployee Director Stock Option Plan (the "PHAMIS Director Plan") which
were outstanding at the effective date of the Merger were effectively assumed by
IDX based on the exchange of .73 shares of IDX Common Stock for each share of
PHAMIS Common Stock. Pursuant to the terms of the aforementioned plans, all
unvested and unexercisable option grants were fully vested and became
exercisable immediately prior to the Merger. The aforementioned PHAMIS plans
were terminated for purposes of prospective eligibility at the effective time of
the Merger. At December 31, 1997, options to purchase 45,542, 214,832 and 3,650
shares of IDX Common Stock were outstanding and exercisable under the 1983
Option Plan, the 1993 Option Plan and the PHAMIS Director Plan, respectively.

Stock Based Compensation

Pro forma information regarding net income and net income per share is
required by SFAS No. 123, and has been determined as if the Company had
accounted for its employee stock options and shares issued pursuant to the ESPP
under the fair value method of that Statement. The fair value for these options
and shares issued pursuant to the ESPP were estimated at the date of grant using
the Black-Scholes option pricing model with the following weighted average
assumptions:

Options ESPP
------- ----
1997 1996 1995 1997 1996 1995
----- ------ ---- ------ ---- ----

Expected life (years).... 6.3 6.3 3.3 .5 .55 .3
Interest rate............ 6.0% 6.4% 6.1% 6.1% 6.3% 5.7%
Volatility............... 42.7% 43.3% 29.3% 42.7% 40.4% 62.5%
Dividend yield........... 0.0% 0.0% 0.0% 0.0% 0.0% 0.0%

The Black-Scholes option valuation model was developed for use in
estimating the fair value of traded options which have no vesting restrictions
and are fully transferable. In addition, option valuation models require the
input of highly subjective assumptions including the expected stock price
volatility. Because the Company's employee stock options have characteristics
significantly different from those of traded options, and because changes in the
subjective input assumptions can materially affect the fair value estimate, in
management's opinion, the existing models do not necessarily provide a reliable
single measure of the fair value of its employee stock options.

For purposes of pro forma disclosures, the estimated fair value of the
options is amortized to expense over the options' vesting period. The Company's
pro forma information follows (in thousands, except for net income per share
information):

1997 1996 1995
----- ---- ----

Pro forma net income............... $ 467 $14,285 $13,360
Pro forma net income per share..... $ 0.02 $ 0.55 $ 0.60

Pro forma net income and net income per share in 1997 includes the effect
of accelerated vesting of all outstanding options of PHAMIS as of the merger.
The effect of accelerated vesting was to reduce pro forma net income from
$3,812,000 to $467,000 and to reduce pro forma net income per share from $0.15
to $0.02.

The effects on 1995, 1996 and 1997 pro forma net income and net income per
share of expensing the estimated fair value of stock options and shares issued
pursuant to the ESPP are not necessarily representative of the effects on
reporting the results of operations for future years as the periods presented
include only one, two and three years of option grants under the Company's
plans.

Stock Based Compensation (continued)

A summary of the Company's stock option activity, and related information
for the years ended December 31 follows:

1997 1996 1995
---- ---- ----
Weighted- Weighted- Weighted-
Average Average Average
Exercise Exercise Exercise
Options Price Options Price Options Price

Outstanding at beginning of
year 1,950,916 $17.88 1,702,936 $8.18 3,119,780 $3.49
Granted 679,129 $30.78 873,906 $28.54 618,432 $13.20
Exercised (494,706) $12.28 (579,130) $5.16 (2,030,896) $2.51
Forfeited (56,412) $25.18 (46,796) $21.54 (4,380) $6.33
------------ ------------ --------------

Outstanding at end of year 2,078,927 $24.73 1,950,916 $17.88 1,702,936 $8.18
============ ============ ==============

Exercisable at end of year 805,073 $16.73 777,732 $7.22
============ ============

Weighted-average fair value of
options granted during the
year $16.56 $14.94

Available for future grants 2,553,424 821,578
============ ============

The following table presents weighted-average price and life information
about significant option groups outstanding at December 31, 1997:

Options Outstanding Options Exercisable
------------------------------ ---------------------
Weighted- Weighted- Weighted
-------- -------- --------
Average Average Average
------- ------- -------
Range of Number Remaining Exercise Number Exercise
-------- ------ --------- -------- ------ --------
Exercise Prices Outstanding Contractual Life Price Exercisable Price
--------------- ----------- ---------------- ----- ----------- -----

$3.97 - $5.14 174,200 6.25 years $ 4.67 174,200 $ 4.67
$5.18 - $6.58 154,291 4.17 years $ 6.25 154,291 $ 6.25
$7.82 - $17.29 41,315 3.88 years $ 8.46 41,315 $ 8.46
$18.00 - $25.63 306,695 7.95 years $ 18.93 161,194 $ 19.41
$26.03 - 38.87 1,402,426 9.09 years $ 31.00 274,073 $ 29.95
--------- -------
2,078,927 805,073
========= =======

13. Quarterly Information (Unaudited)

A summary of operating results and pro forma net income (loss) per share
for the quarterly periods in the two years ended December 31, 1997 is set forth
below:

Quarter Ended
---------------------------------------------------------
March 31 June 30 September 30 December 31 Total
-------- ------- ------------ ----------- -----
(in thousands, except per share amounts)

Year ended December 31, 1997
Total revenues.................. $59,559 $57,432 $64,598 $69,828 $251,417
Gross profit.................... 29,595 26,371 30,986 34,041 120,993
Net income (loss)............... 4,498 3,875 (7,355) 6,944 7,962
Net income (loss) per share -
basic......................... $0.18 $0.15 $( 0.29) $0.27 $0.31
Net income (loss) per share -
diluted....................... $0.17 $0.15 $ (0.28) $0.26 $0.30

Year ended December 31, 1996
Total revenues.................. $49,460 $51,242 $51,402 $54,775 $206,879
Gross profit.................... 23,069 25,027 24,240 26,280 98,616
Net income...................... 3,708 4,323 4,100 4,529 16,660
Net income per share - basic.... $0.15 $0.17 $0.16 $0.18 $0.66
Net income per share - diluted. $0.14 $0.17 $0.16 $0.17 $0.64

The 1996 and first three quarters of 1997 net income (loss) per share amounts
have been restated to comply with Statement of Financial Accounting Standards
No. 128, Earnings per Share, and to reflect the Merger with PHAMIS which was
accounted for as a pooling of inetrests.

SCHEDULE II--VALUATION AND QUALIFYING ACCOUNTS

- --------------------------------------------------------------------------------------------------------------------
Balance at Charged to Charged to Bad Debts Balance at
Beginning Costs and Other Written Off Net End of
Description of Period Expenses Accounts of Collections Period

- -----------------------------------------------------------------------------------------------------------------------
Year ended December 31, 1997:
- -----------------------------------------------------------------------------------------------------------------------
Allowance for doubtful accounts $787,000 $593,000 $112,000 $1,268,000
- -----------------------------------------------------------------------------------------------------------------------
Year ended December 31, 1996:
- -----------------------------------------------------------------------------------------------------------------------
Allowance for doubtful accounts $592,000 $360,000 $165,000 $ 787,000
- -----------------------------------------------------------------------------------------------------------------------
Year ended December 31, 1995:
- -----------------------------------------------------------------------------------------------------------------------
Allowance for doubtful accounts $480,000 $387,000 $275,000 $ 592,000
- -----------------------------------------------------------------------------------------------------------------------

Item 9. Changes in and Disagreements with Accountants on Accounting and
Financial Disclosure

There have been no changes in or disagreements with the Company's accountants on
accounting or financial disclosure during the two most recent fiscal years or
any subsequent interim period.

PART III

Item 10. Directors and Officers of the Registrant

The response to this item is contained in part under the caption "Executive
Officers of the Registrant" in Part I hereof, and the remainder is contained in
the Company's 1998 Proxy Statement under the caption "Election of Directors" and
is incorporated herein by reference.

Item 11. Executive Compensation

The response to this item is contained in this Company's 1998 Proxy Statement
under the captions "Board of Directors Compensation" and "Compensation of
Executive Officers" and is incorporated herein by reference. Information
relating to delinquent filings of Forms 3, 4 and 5 of the Company is contained
in the Company's 1998 Proxy Statement under the caption "Compliance with Section
16 Reporting Requirements."

Item 12. Security Ownership of Certain Beneficial Owners and Management

The response to this item is contained in the Company's 1998 Proxy Statement
under the caption "Security Ownership of Certain Beneficial Owners and
Management" and is incorporated herein by reference.

Item 13. Certain Relationships and Related Transactions

The response to this item is contained in the Company's 1998 Proxy Statement
under the captions "Compensation Committee Interlocks and Insider Participation"
and "Certain Relationships and Related Transactions" and is incorporated herein
by reference.
PART IV

Item 14. Exhibits, Financial Statement Schedules, and Reports on Form 8-K

Page
----

(a) The following consolidated financial statements of IDX Systems Corporation
are included in Item 8.
1. Consolidated Balance Sheets at December 31, 1997 and 1996.................. 24
Consolidated Statements of Income for the Years Ended December 31, 1997,
1996 and 1995.............................................................. 25
Consolidated Statements of Stockholders' Equity for the Years Ended
December 31, 1997, 1996 and 1995........................................... 26
Consolidated Statements of Cash Flows for the Years Ended December 31,
1997, 1996 and 1994........................................................ 27
Notes to the Consolidated Financial Statements............................. 28
Report of Independent Auditors on Financial Statements..................... 22
2. The consolidated financial statement Schedule II is included in Item 8.
All other schedules are omitted as the information required is inapplicable.
3. The Exhibits listed in the Exhibit Index immediately preceding the Exhibits
are filed as a part of this Annual Report on Form 10-K.

(b) No Current Reports on Form 8-K were filed by the Company during the last
quarter of the period covered by this report.

SIGNATURES

Pursuant to the requirements of the Section 13 or 15(d) of the Securities
Exchange Act of 1934, the registrant has duly caused this report to be signed on
its behalf by the undersigned, thereunto duly authorized on the 25th day of
March, 1998.

IDX SYSTEMS CORPORATION

By: /s/ Richard E. Tarrant
----------------------------------
Richard E. Tarrant,
President and Chief Executive Officer

Pursuant to the requirements of the Securities Exchange Act of 1934, this
report has been signed below by the following persons on behalf of the
registrant and in the capacities and on the dates indicated.

Signature Title Date
- --------- ----- ----

/s/ Richard E. Tarrant President, Chief. March 25, 1998
- ----------------------------- Executive Officer and
Richard E. Tarrant Director (Principal Executive Officer)

/s/ John A. Kane Vice President, Finance March 25, 1998
- ----------------------------- and Administration, Chief
John A. Kane Financial Officer and Treasurer
(Principal Financial and
Accounting Officer)

/s/ Paul L. Egerman Director March 23,1998
- -----------------------------
Paul L. Egerman

/s/ Henry M. Tufo Director March 25, 1998
- ----------------------------
Henry M. Tufo, M.D.

/s/ Robert H. Hoehl Director March 27, 1998
- ----------------------------
Robert H. Hoehl

/s/ Stuart H. Altman Director March 23, 1998
- ----------------------------
Stuart H. Altman, Ph.D.

/s/ Steven M. Lash Director March 21, 1998
- -------------------------------
Steven M. Lash

/s/ Frank T. Sample Director March 23, 1998
- -------------------------------
Frank T. Sample

/s/ Malcolm A. Gleser Director March 27, 1998
- -------------------------------
Malcolm A. Gleser, M.D., Ph.D.

Exhibit Index

The following exhibits are filed as part of this Annual Report on Form
10-K.

Exhibit No. Description Page
- ----------- ----------- ----
3.1* Second Amended and Restated Articles of Incorporation.

3.2* Second Amended and Restated bylaws.

4.1* Specimen Certificate for shares of Common Stock, $.01 par value,
of the Registrant.

10.1#* 1985 Incentive Stock Option Plan.

10.2#* 1994 Incentive Stock Option Plan.

10.3#* 1995 Stock Option Plan.

10.4#* 1995 Director Stock Option Plan.

10.5#* 1995 Employee Stock Purchase Plan.

10.6#* Description of Registrant's Executive Bonus Plan.

10.7* Agreement between Richard E. Tarrant, Robert H. Hoehl and Paul L.
Egerman dated as of June 24, 1994.

10.8* Agreement between the Registrant, Richard E. Tarrant, Robert H.
Hoehl and Paul L.Egerman dated as of September 18, 1995.

10.9#* Amended and Restated Consulting/Employment Agreement between the
Registrant and Henry M. Tufo, dated as of March 7, 1995, and
related Letter Agreement between Mr. Tufo and the Registrant dated
August 11, 1995.

10.10* Employment, Noncompetition and Nondisclosure Agreement between the
Registrant and Richard E. Tarrant.

10.11* Employment, Noncompetition and Nondisclosure Agreement between the
Registrant and Robert H. Hoehl.

10.12* Employment, Nondisclosure and Noncompetition Agreement between the
Registrant and Jeffrey M. Blanchard dated in 1987.

10.13* Employment, Noncompetition and Nondisclosure Agreement between the
Registrant and James H. Crook, Jr. dated September 19, 1995.

10.14* Agreement between the Registrant and Robert F. Galin dated
April 5, 1982.

10.15* Employment Agreement between the Registrant and John A. Kane dated
October 15, 1984.

10.16* Redemption Agreement between the Registrant, Richard E. Tarrant and
Robert H. Hoehl dated as of April 1, 1993.

10.17* First Amendment to Redemption Agreement between the Registrant,
Richard E. Tarrant and Robert H. Hoehl.

Exhibit No. Description Page
- ----------- ----------- ----
10.18* Amended and Restated Certificate and Agreement of Limited
Partnership of 4901 LBJ Limited Partnership between the Registrant
and Richard E. Tarrant, Robert H. Hoehl, Paul L. Egerman, John A.
Kane, Robert F. Galin and certain of the Registrant's employees
dated as of April 1, 1992, as amended on July 1, 1993.

10.19* Lease Agreement between the Registrant and 4901 LBJ Limited
Partnership dated as of April 7, 1992.

10.20* Indenture of Lease between the Registrant and IDS Realty Trust
dated as of December 1, 1981, as amended on June 29, 1995.

10.21* Lease Agreement between the Registrant and BDP Realty Associates
relating to 1500 Shelburne Road dated July 6, 1979.

10.22* Extension of Lease Agreement between the Registrant and BDP Realty
Associates relating to 1500 Shelburne Road dated as of August 16,
1995.

10.23* Guaranty Modification Agreement relating to 1400 Shelburne Road
dated as of September 15, 1995.

10.24* Reimbursement Agreement among the Registrant, BDP Realty Associates
and State Street Bank and Trust Company dated as of January 25,
1993.

10.25* Agreement of Lease between the Registrant and Huntington Avenue
Limited Partnership dated as of April 13, 1994, as amended through
January 1, 1995.

10.26* Guaranty Release Agreement relating to 116 Huntington Avenue.

10.27* Option Agreement between the Registrant and BDP Realty Associates.

10.28* Tax Indemnification Agreement between the Registrant and the
stockholders listed on Schedule A thereto.

10.29* Employment, Noncompetition and Nondisclosure Agreement between the
Registrant and Pamela J. Pure effective April 3, 1995.

10.30#* Letter Agreement between the Registrant and Pamela J. Pure dated
March 7, 1995.

10.31#* Letter Agreement between the Registrant and Pamela J. Pure dated
October 23, 1995.

10.32#* Nonqualified Stock Option Agreement dated as of September 1, 1991
between the Registrant and John A. Kane.

10.33#* Nonqualified Stock Option Agreement dated as of September 1, 1992
between the Registrant and John A. Kane.

10.34# Letter Agreement between the Registrant and Jeffrey V. Sutherland,
Ph.D. dated August 16, 1996

10.35# Employment, Noncompetition and Nondisclosure Agreement between the
Registrant and Jeffrey V. Sutherland, Ph.D. dated September, 1996.

10.36+ Agreement and Plan of Merger dated as of March 25, 1997 by and
among the Registrant, Penguin Acquisition Corporation and
PHAMIS, Inc.

Exhibit No. Description Page
- ----------- ----------- ----

10.37#@ PHAMIS, Inc. Amended and Restated 1983 Combined Nonqualified and
Incentive Stock Option Plan

10.38#@ PHAMIS, Inc. 1993 Combined Incentive and Nonqualified Stock Option
Plan as amended through May 14, 1996

10.39#@ PHAMIS, Inc. 1994 Nonemployee Director Stock Option Plan as amended
through January 1, 1996

10.40#@ PHAMIS, Inc. Salary Savings and Deferral Plan and Trust as amended
through February 22, 1996

10.41#@ Stock Option Agreement dated August 20, 1990 between PHAMIS, Inc.
and Michael Cain.

10.42 Amended and Restated Lease Agreement between BDP Realty
Associates and IDX Systems Corporation dated as of
November 1, 1997

23.1 Consent of Ernst & Young LLP

23.2 Consent of KPMG Peat Marwick LLP

27.1 Financial Data Schedule

27.2 Restated Financial Data Schedule for each 12 Month Period from
1995-1997

27.3 Restated Financial Data Schedule for First Three Quarters of 1996

27.4 Restated Financial Data Schedule for First Three Quarters of 1997

# Management contract or compensatory plan or arrangement filed as an exhibit
to or incorporated by reference into this Form pursuant to Items 14(a) and
14(c) of Form 10-K.
* Incorporated herein by reference from the Company's Registration Statement on
Form S-1, as amended (File No. 33-97104).
+ Incorporated herein by reference from the Company's Registration Statement on
Form S-4, as amended (File No. 333-2891).
@ Incorporated herein by reference from the Company's Registration Statement on
Form S-8, as amended (File No. 333-31045).